RAGE TUMOR REJECTION ANTIGENS

Abstract: The invention describes the RAGE tumor rejection antigen precursor family, including nucleic acids encoding such tumor rejection antigen precursors, tumor rejection antigen peptides or precursors thereof and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a RAGE tumor rejection antigen precursor.

Description: RAGE TUMOR REJECTION ANTIGENS Field of the Invention This invention relates to nucleic acid molecules which code for tumor rejection antigens and precursors thereof. The tumor rejection antigen precursors are processed, inter alia, into at least one tumor rejection antigen thai is presented by HLA molecules. The nucleic acid molecules, proteins coded for by such molecules and peptides derived therefrom, as well as related antibodies and cytotoxic lymphocytes, are useful, inter alia, in diagnostic and therapeutic contexts. Background of the Invention The process by which the mammalian immune system recognizes and reacts to foreign or alien materials is complex. An important facet of tine system is the T cell response. T cells can recognize and interact with other cells via cell surface complexes on the other cells of peptides and molecules referred to as human leukocyte antigens ("HLA") or major histocompatibility complexes ("MHCs"). The peptides are derived from larger molecules which are processed by the cells which also present the HLA/MHC molecule. See Male et al., Advanced Immunology (J.P. Lipincott Company, 1987), especially chapters 6-10. The interaction of T cells and complexes of HLA/peptide is restricted, requiring a specific T cell for a specific complex of an HLA molecule and a peptide. If a specific T cell is not present, there is no T cell response even if its partner complex is present Similarly, there is no response if the specific complex is absent, but the T cell is present The mechanism is involved in the immune system's response to foreign materials, in autoimmune pathologies, and in responses to cellular abnormalities. The mechanism by which T cells recognize alien materials also has been implicated in cancer. A number of cytolytic T lymphocyte (CTL) clones directed against autologous melanoma have been described. In some instances, the antigens recognized by these clones have been characterized. In PCT application PCT/US92/04354, published on November 26, 1992, the "MAGE" family, a tumor specific family of genes, is disclosed. The expression products of these genes are processed into peptides which, in turn, are expressed on cell surfaces. This can lead to lysis of the tumor cells by specific CTLs. The genes are said to code for "tumor rejection antigen precursors" or "TRAP" molecules, and the peptides derived therefrom are referred to as "tumor rejection antigens" or "TRAs". See Traversari et al., Immunogenetics 35: 145 (1992); van der Bruggen et al., Science 254: 1643 (1991), for further infomiation on this family of genes. Also, see U.S. Patent No. 5342,774. In U.S. Patent 5,405,940, MAGE nonapeptides are taught which are presented by the HLA-A1 molecule. Given the known specificity of particular peptides for particular HLA molecules, one should expect a particular peptide to bind one HLA molecule, but not others. This is important because different individuals possess different HLA phenotypes. As a result while identification of a particular peptide as being a partner for a specific HLA molecule has diagnostic and therapeutic ramifications, these are only relevant for individuals with that particular HLA phenotype. There is a need for further work in the area- because cellular abnormalities are not restricted to one particular HLA phenotype, and targeted therapy requires some knowledge of the phenotype of the abnormal cells at issue. It also was discovered that a MAGE expression product is processed to a second TRA. This second TRA is presented by HLA-C clone 10 molecules. Therefore, a given TRAP can yield a plurality of TRAs. In PCT WO94/14459, published July 7. 1994, tyrosinase is described as a tumor rejection antigen precursor. This reference discloses that a molecule which is produced by some normal cells (e.g.. melanocytes). is processed in tumor cells to yield a tumor rejection antigen that is presented by HLA-A2 molecules. In PCT WO94 21126, published September 29, 1994. a second TRA, not derived fiom tyrosinase is taught to be presented by HLA-A2 molecules. The TRA is derived from a TRAP, but is coded for by a non-MAGE gene. This disclosure shows that a particular HLA molecule may present TRAs derived from different sources. In PCT WO95/00159, published January 5. 1995. an unrelated tumor rejection antigen precursor, the so-called "BAGE" precursor, is described. TRAs are derived from the TRAP and also are described. They form complexes with MHC molecule HLA-C-Clone 10. In PCT WO95/03422, published February 2. 1995. another unrelated tumor rejection antigen precursor, the so-called "GAGE" precursor, is described. The GAGE precursor is not related to the BAGE or the MAGE femily. The work which is presented by the papers, patents and patent applications described above deal, for the most part with the MAGE family of genes, the BAGE gene and the GAGE gene. These genes are expressed in a number of tumors but are completely silent in normal tissues except testis. None is expressed in renal carcinoma It now has been discovered that another gene family, the "RAGE" genes, encodes additional tumor rejection antigens and precursors thereof. The RAGE genes do not show homolog}' to the MAGE farnily of genes, to the BAGE gene or the GAGE gene. The RAGE genes are expressed in renal tumor cells, but not in normal renal cells. The RAGE genes are also expressed in certain other tumor cell types. - j - The invention is elaborated upon in the disclosure which follows. Summary of the Invention The invention provides isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides. and antibodies to those proteins and peptides. Kits containing the foregoing molecules additionally are provided. The foregoing can be used in the diagnosis or treatment of conditions characterized by the expression of a RAGE TRA or TRAP. According to one aspect of the invention, an isolated polypeptide is provided. It includes at least the amino acid sequence of SEQ.ID.NO.40 and is a RAGE TRA. In preferred embodiments, the isolated polypeptide includes at least the amino acid sequence of SEQ.ID.NO.43. In other embodiments the isolated polypeptide may consist essentially of or may even be only the amino acid sequence of SEQ.ID.NO.40 or SEQ.ID.NO.43. According to another aspect of the invention, an isolated nucleic acid molecule is provided. The molecule encodes a polypeptide selected from the group consisting of SEQ.ID.NO.40 and SEQ.ID.NO.43. The isolated nucleic acid can include SEQ.ID.NO.44 and preferably includes SEQ.ID.NO.45. In other embodiments the isolated nucleic acid may consist essentially of or may even be only SEQ.ID.NOs.44 or 45. According to another aspect of the inventioa an isolated nucleic acid molecule is provided which hybridizes under stringent conditions to a molecule consisting of the nucleic acid sequence of SEQ.ID.NO.1. SEQ.ID.NO.4. SEQ.ID.NO.6. SEQ.ID.NO.10. SEQ.ID.NO.12. SEQ.ID. NO.13. SEQJ0D.NO.14. SEQ.ID.NO.15. SEQ.ID.NO.17. SEQ.ID.NO.23. and/or SEQ.ID.NO.35. and which codes for RAGE TRAs or TRAPs. with the proviso that the isolated nucleic acid molecule does not code for a MAGE. GAGE or BAGE TRA or TRAP. In preferred embodiments, the isolated nucleic acid molecule is an mRNA molecule or a cDNA molecule. In one embodiment the isolated nucleic acid molecule is complementary to nucleotides selected fiom the group consisting of 204 to 326 of SEQ.ID.NO.1. 313 to 399 of SEQ.ID.NO.1. 444 to 665 of SEQ.DD.NO.1.273 to 449 of SEQ.ID.NO.12.217 to 276 of SEQ.ID.NO.12. 185 to 247 of SEQ.ID.NO.13 and 269 to 832 of SEQ.ID.NO.14. In another embodiment the isolated nucleic acid consists essentially of SEQ.ID.NO.1, SEQ.ID.NO.4. SEQ.ID. NO.6. SEQ.ID.NO.10. SEQ.ID.NO.12. SEQ.ID. NO.13. SEQ.ID.NO.14, SEQ.ID.NO.15. SEQ.ID.NO.17. SEQ.ID.NO.23. SEQ.ID.NO.35. SEQ.ID.NO.44 and/or SEQ.ID.NO.45. According to another aspect of the invention, expression vectors and host cells containing those expression vectors are provided. The expression vectors include any one or more of the isolated nucleic acid molecules described above. In one embodiment the expression vector comprises the isolated nucleic acid of SEQ.ID.NOs.44 or 45. Other expression vectors according to the invention include the isolated nucleic acids described above and a nucleic acid which codes for an HLA molecule which can present the TRAs of the invention to cytolytic T cells. One example is HLA-B7. The host cells may endogenously express the HLA molecule such as HLA-B7. According to another aspect of the invention, isolated nucleic acid molecules that are unique fiagments of SEQ.ID.NO.1, SEQ.ID.NO.12, SEQ.ID.NO.13 or SEQ.ID.NO.14 or their complements are provided. Such unique fragments are used to identify or to selectively amplify the nucleic acids described above. When the unique fragments are used for identifying expression of the above nucleic acids, the unique fragments preferably are between 200 and 1310 nucleotides in length.200 and 1234 nucleotides in length. 200 and 2050 nucleotides in length or 200 and 1167 nucleotides in length. When the unique fragments are used to amplify the above-described nucleic acid molecules, the unique fragments are between 12 and 32 nucleotides in length. It will be recognized that amplification procedures are not exclusive of procedures that might be used to identify a nucleic acid molecule. According to another aspect of the invention, kits for detecting the presence of expression of a TRA or TRAP are provided. Such kits employ two or more of the above-described molecules isolated in separate containers and packaged in a single package. In one such kit a pair of amplification primers are provided- each of the pair consisting essentially of a 12-32 in length nucleotide contiguous segment of SEQ.ID.NO.1 or the complement thereof. SEQ.ID.NO.12 or the complement thereof. SEQ.ID.NO.13 or the complement thereof, or SEQ.ID.NO.14 or the complement thereof, and wherein the contiguous segments are non- overlapping. Preferably the amplification primers are PCR primers, wherein one of the primers is a contiguous segment of the Watson strand and another of the primers is the complement of a contiguous segment of Crick strand. In certain embodiments, primers are constructed and arranged to selectively amplify and/or identify only one of the RAGE family, such as only RAGE 1 or a portion of only RAGE 1. etc. For example, one of the pair can be contiguous in RAGE 1 genes and allelic variants thereof but not contiguous in RAGE 2, 3 or 4 genes. More specifically as an example . a first primer can be a nucleic acid consisting essentially of any one of SEQ.ID.NOs.50-57. and a second primer can consist essentially of a 12-32 in length nucleotide contiguous segment of SEQ.ID.NO.1. or the complement thereof, depending upon the choice of the first primer. Another kit according to the invention is an expression kit comprising a separate portion of the isolated nucleic acid molecule which codes for a RAGE TRAP, or a molecule including a RAGE TRA. and an HLA presenting molecule that forms a complex with that TRA and that stimulates a cytolytic T cell response. One such kit includes a nucleic acid which codes for the peptide of SEQ.ID.NO.40 or SEQ.ID.NO.43 and a nucleic acid molecule which codes for HLA-B7. Another kit according to the invention is an expression kit comprising a separate portion of the isolated nucleic acid molecule which hybridizes under stringent conditions to a molecule consisting of the nucleic acid sequence of SEQ.ID.NO.1. SEQ.ID.NO.4. SEQ.ID.NO.6, SEQ.ID.NO.10. SEQ.ID.12. SEQ.ID.13. SEQ.ID.14. SEQ.ID.15. SEQ.ID.17. SEQ.ID.23 and/or SEQ.ID.35 and which codes for a RAGE TRAP, and a nucleic acid molecule which codes for HLA-B7. According to another aspect of the invention isolated TRAPs coded for by the above molecules and useful fragments thereof also are provided. Antibodies to such molecules and to complexes of HLA and RAGE TRAs also are provided. According to another aspect of the invention, methods for diagnosing a disorder characterized by expression of a RAGE TRAP are provided. One method involves a RAGE TRAP which is processed to a RAGE derived TRA that forms a complex with HLA molecules. The method involves contacting a biological sample isolated from a subject with an agent that binds the complex and then determining binding between the complex and the agent as a determination of the disorder. In one embodiment the method determines binding of Ihe agent to a complex of RAGE TRA and HLA-B7. In this embodiment the RAGE TRA can be selected from the group consisting of the peptide of SEQ.ID.NO.40 and the peptide of SEQ.ID.NO.43. Another method involves contacting a biological sample isolated from a subject with an agent that is specific for a RAGE nucleic acid or an expression product thereof. Interaction between the agent and the nucleic acid or expression product thereof then is determined interaction being indicative of the disorder. The agent may be a nucleic acid which hybridizes under stringent conditions to a molecule consisting of the nucleic acid sequence selected from the group consisting of SEQ.ID.NO.1. SEQ.ID.NO.4. SEQ.ID.NO.6. SEQ.ID.NO.10. SEQ.ID.NO.12. SEQ.ID. NO.13. SEQ.ID.NO.14. SEQ.ED.NO.15. SEQ.ID.NO.17, SEQ.ID.NO.23 and SEQ.ID.NO.35. and which codes for a TRAP, with the proviso that the isolated nucleic acid molecule does not code for a MAGE. GAGE, or BAGE TRAP. Another method involves contacting a biological sample isolated from a subject with an agent that is specific for a RAGE tumor rejection antigen peptide and then determining interaction between the peptide and the agent as a determination of the disorder. In one embodiment the peptide is selected from the group consisting of SEQ.ID.NO.40 and SEQ.E .NO.43. According to another aspect of the invention, an isolated biological preparation is provided. The preparation consists essentially of cytolytic T cells specific for complexes of an HLA molecule and a RAGE TRA. In one embodiment the cytolytic T cells are specific for complexes of an HLA-B7 molecule and the - o - TRA. In this embodiment the antigen can be a peptide selected from the group consisting of the peptide of SEQ.ID.NO.40 and the peptide of SEQ.ID.NO.43. Another aspect of the invention thus involves a method for enriching selectively a population of T cells with cytolytic T cells specific for complexes of an HLA molecule and a RAGE TRA. The method involves contacting an isolated population of T cells containing cytolytic T cell precursors with an agent resulting in presentation of a complex of a RAGE TRA and HLA presenting molecule, in an amount sufficient to selectively enrich the isolated population of T cells with said cytolytic T cells. In one preferred embodiment the HLA molecule is HLA-B7 and the RAGE TRA is selected from the group consisting of a peptide consisting of the amino acids of SEQ.ID.NO.40 and a peptide consisting of the amino acids of SEQ.ID.NO.43. Still another aspect of the invention involves methods for treating a subject with a disorder characterized by expression of a RAGE TRA or TRAP. One such method involves administering to a subject in need of such treatment an effective amount of an agent which enriches selectively in the subject the presence of complexes of HLA and RAGE TRA resulting in cytolytic T cell response reactive with such complexes, sufficient to ameliorate the disorder. Such agents include the RAGE TRAPs and recombinant cells expressing complexes of the HLA and RAGE TRA. In one embodiment such agents include cells expressing a complex of HLA-B7 and a peptide consisting of the peptide of SEQ.ID.NO .40 or the peptide of SEQ.ID.NO.43. Another method involves administering to a subject in need of such treatment an amount of autologous cytolytic T cells sufficient to ameliorate the disorder, wherein the autologous cytolytic T cells are specific for complexes of an HLA molecule and a RAGE TRA. In connection with any isolated nucleic acid encoding a TRAP or TRA as described above, the invention also embraces degenerate nucleic acids that differ from the isolated nucleic acid in codon sequence only due to the degeneracy of the genetic code or complements of any of the foregoing nucleic acids. The invention also embraces functional variants and equivalents of all of the molecules described above. The invention also involves the discovery and isolation of TRAPs and TRAs which are expressed in tumor cells, particularly in renal tumor cells, and not expressed in normal renal cells. Prior to the present invention. TRAPs and/or TRAs of the type described herein were not known and identified for renal carcinomas, despite the knowledge and identity of other TRAPs and TRAs for numerous other cell types. Surprisingly, the RAGE-1 gene of the present invention was expressed in only 1 of 57 renal carcinomas, and the best antigenic peptide for a particular cytotoxic T cell clone was discovered to be a decamer. not the usual nonamer peptide. Thus, according to another aspect of the invention, the invention provides TRAPs. TRAs and nucleic acids coding for TRAPs and TRAs, which are not MAGE. BAGE AND GAGE TRAPs. TRAs and nucleic acids, which are expressed in tumor cells, particularly in renal tumor cells but not in normal renal cells, and are obtainable by a process comprising isolating renal tumor cells from a patient isolating lymphocytes from the patient contacting the renal tumor cells with the lymphocytes in vitro. isolating a cytotoxic T cell clone among the lymphocytes reactive with the renal tumor cells. preparing an expression library from mRNA of the renal tumor cells. screening the expression library with the cytotoxic T cell clone for a library member reactive with the cytotoxic T cell clone. isolating said library member reactive with the cytotoxic T cell clone, and sequencing the renal cell nucleic acid in said library member, said renal cell nucleic acid encoding the TRAP (or portion thereof) including the TRA. The invention also provides sequences having homology to such nucleic acids and coding for renal associated TRAPs and TRAs. sequences which hybridize under stringent conditions to such nucleic acids and coding for renal associated TRAPs and TRAs. complements, unique fragments and 'degenerates' of the foregoing, the TRAPs and TRAs themselves, as well as functional variants and equivalents of any of the foregoing, all of which can be considered to be RAGE nucleic acids. TRAPs and TRAs. The invention also provides agents that selectively enrich in a subject the presence of complexes of HLA/RAGE TRAs for use as a medicament. Such agents include, but are not limited to. RAGE TRAs and/or RAGE TRAPs; recombinant cells expressing RAGE TRAs and/or RAGE TRAPs and also expressing appropriate HLA molecules, recombinant or not: and functional variants and equivalents of the foregoing. Specific examples include the RAGE TRA of SEQ.ID.NO. 43: any fragment of the RAGE TRAP of SEQ.ID.NO. 5 including the TRA of SEQ.ID.NO.43: the RAGE TRAP of SEQ.ID.NO. 5: recombinant cells expressing the TRA of SEQ.ID.NO.43 and HLA-B7; and/or any other RAGE TRA. RAGE TRAP or functional fragment thereof and/or cells expressing such molecules. The invention also provides agents that selectively enrich in a subject the presence of complexes of HLA/RAGE TRAs in the manufacture of a medicament for treating cancer. Such agents include, but are not limited to. RAGE TRAs and/or RAGE TRAPs; recombinant cells expressing RAGE TRAs and/or RAGE TRAPs and also expressing appropriate HLA molecules, recombinant or not: and functional variants and equivalents of the foregoing. Specific examples include the RAGE TRA of SEQ.ID.NO.43: any fragment of the RAGE TRAP of SEQ.ID.NO. 5 including the TRA of SEQ.ID.NO.43; the RAGE TRAP of - o - SEQ.ID.NO. 5; recombinant cells expressing the TRA of SEQ.ED.NO.43 and HLA-B7; and/or any other RAGE TRA, RAGE TRAP or functional fragment thereof and/or cells expressing such molecules. The invention also provides cytotoxic T cells specific for complexes of HLA and RAGE TRA for use as a medicament. One nonlimiting example is autologous cytotoxic T cells specific for tumor cells expressing complexes of HLA-B7 and RAGE TRA. The invention also provides cytotoxic T cells specific for complexes of HLA and RAGE TRA in the manufacture of a medicament for treating cancer. One nonlimiting example is autologous cytotoxic T cells specific for tumor cells expressing complexes of HLA-B7 and RAGE TRA. The invention also provides pharmaceutical preparations containing any one or more of the medicaments described above or throughout the specification. Such pharmaceutical preparations can include phaimaceutically acceptable diluent carriers or excipients. These and other objects of the invention will be described in further detail in connection with the detailed description of the invention Brief Description of the Drawings Figure 1 is a graph showing the levels of tumor necrosis factor produced when CTL Clone 263/17 is combined with COS cells transfected with HLA-B7 cDNA and a cDNA encoding a RAGE TRAP. Figure 2 is a schematic representation of the RAGE-1.2.3 and 4 cDNAs. Closed black boxes indicate the different ORF in each of the three reading frames. Shaded areas in the RAGE-2, 3 and 4 cDNAs represent sequences that are unrelated to the RAGE-1 sequence, including two insertions. The 5' terminal sequence obtained by PCR is indicated with dashed boxes. The 3' end of this PCR sequence is identical to the overlapping 5' end sequences of the RAGE-2, 3 and 4 cDNAs. The antigenic peptide encoded by RAGE-1 is indicated. Figure 3 is a graph showing the levels of tumor necrosis factor produced when CTL Clone 263/17 is combined with COS cells transfected with HLA-B7 cDNA and a cDNA encoding a RAGE TRAP or a minigene encoding ORF2 of a RAGE TRAP. Figure 4 is a graph detailing the levels of tumor necrosis factor produced when CTL Clone 263/17 is combined with peptide fragments of the TRAP encoded by ORF2 of the RAGE gene and COS cells transfected with HLA-B7. Figure 5 is a graph depicting the lytic activity of CTL clone 267/17 against HLA-B7 " LB23-EBV B cells pulsed with increasing concentrations of the peptides including a RAGE TRA. Brief Description of the Sequences SEQ.ID.NO.1 is the nucleotide sequence of the RAGE-1 cDNA SEQ.ID.NO.2 is open reading frame 1 (ORF1) of the cDNA of SEQ.ID.NO.1. SEQ.ID.NO.3 is the translated amino acid sequence of SEQ.ID.NO2. 5 SEQ.ID.NO.4 is open reading frame 2 (ORF2) of the cDNA of SEQ.ID.NO.1. SEQ.ID.NO.5 is the translated amino acid sequence of SEQ.ID.NO.4. SEQ.ID.NO.6 is open reading frame 3 (ORF3) of the cDNA of SEQ.ID.NO.1. SEQ.ID.NO.7 is the translated amino acid sequence of SEQ.ID.NO.6. SEQ.ID.NO.8 is open reading frame 4 (ORF4) of the cDNA of SEQ.ID.NO.1. l o SEQ.ID.NO.9 is the translated amino acid sequence of SEQ.ID.NO.8. SEQ.ID.NO.10 is open reading frame 5 (ORF5) of the cDNA of SEQ.ID.NO.1. SEQ.ID.NO.11 is the translated amino acid sequence of SEQ.ID.NO.10. SEQ.ID.NO.12 is the nucleotide sequence of the RAGE-2 cDNA. SEQ.ID.NO.13 is the nucleotide sequence of the RAGE-3 cDNA. 15 SEQ.ID.NO.14 is the nucleotide sequence of the RAGE-4 cDNA SEQ.ID.NO.15 is open reading frame 2' (ORF2') of the cDNA of SEQ.ID.NO.12. SEQ.ID.NO.16 is the translated amino acid sequence of SEQ.ID.NO.15. SEQ.ID.NO.17 is open reading frame 3' (ORF3') of the cDNA of SEQ.ID.NO.12. SEQ.ID.NO.18 is the translated amino acid sequence of SEQ.ID.NO.17. 0 SEQ.ID.NO.19 is open reading frame 4 (ORF4) of the cDNA of SEQ.ID.NO.12. SEQ.ID.NO.20 is the translated amino acid sequence of SEQ.ID.NO.19. SEQ.ID.NO.21 is open reading fiame 5 (ORF5 ) of the cDNA of SEQ.ID.NO.12. SEQ.ID.NO.22 is the translated amino acid sequence of SEQ.ID.NO.21. SEQ.ID.NO.23 is open reading frame 6 (ORF6) of the cDNA of SEQ.ID.NO.13. 5 SEQ.ID.NO.24 is the translated amino acid sequence of SEQ.ID.NO.23. SEQ.ID.NO.25 is open reading frame 2' (ORF2') of the cDNA of SEQ.ID.NO.13. SEQ.ID.NO.26 is the translated amino acid sequence of SEQ.ID.NO.25. SEQ.ID.NO.27 is open reading frame 3' (ORF3') of the cDNA of SEQ.ID.NO.13. SEQ.ID.NO.28 is the translated amino acid sequence of SEQ.ID.NO.27. 0 SEQ.ID.NO.29 is open reading frame 4 (ORF4) of the cDNA of SEQ.ID.NO.13. SEQ.ID.NO.30 is the translated amino acid sequence of SEQ.ID.NO.29. SEQ.ID.NO.31 is open reading frame 5 (ORF5) of the cDNA of SEQ.ID.NO.13. SEQ.ID.NO.32 is the translated amino acid sequence of SEQ.ID.NO.31. SEQ.ID.NO.33 is open reading frame 2' (ORF2') of the cDNA of SEQ.ID.NO.14. SEQ.ID.NO.34 is the translated amino acid sequence of SEQ.ID.NO.33. SEQ.ID.NO.35 is open reading frame 3"(ORF3") of the cDNA of SEQ.ID.NO.14. SEQ.ED.NO.36 is the translated amino acid sequence of SEQ.ID.NO.35. SEQ.ID.NO.37 is open reading fiame 4' (ORF4') of the cDNA of SEQ.ID.NO.14. SEQ.ID.NO.38 is the translated amino acid sequence of SEQ.ID.NO.37. SEQ.DD.NO.39 is the dodecamer peptide containing the RAGE tumor rejection antigen mentioned in connection with Figure 4. SEQ.ID.NO.40 is a nonamer fragment (amino acids 1 -9) of the peptide described in SEQ.ID.NO.39. SEQ.ID.NO.41 is a nonamer fragment (amino acids 2-10) of the peptide described in SEQJDD.NO.39. SEQ.ID.NO.42 is a nonamer fragment (amino acids 3-11) of the peptide described in SEQ.ID.NO.39. SEQ.ID.NO.43 is a decamer fragment (amino acids 1-10) ofthe peptide described in SEQ.ED.NO.39. SEQ.ID.NO.44 is the nucleotide sequence of a DNA which encodes the peptide of SEQ.ID.NO.40. SEQ.ID.NO.45 is the nucleotide sequence of a DNA which encodes the peptide of SEQ.ID.NO.43. SEQ.ID.NO.46 is a sense primer used in PCR tests for expression ofthe RAGE TRAP. SEQ.ID.NO.47 is an antisense primer used in PCR tests for expression of the RAGE TRAP, common to all RAGE genes tested. SEQ.ID.NO.48 is an antisense primer, specific for RAGE-1. used in PCR tests for expression ofthe RAGE-1 TRAP gene. SEQ.ID.NO.49 represents the region of RAGE genes flanking the insertion point of ORF2. with the insertion designated by N. SEQ.ID.NOs.50-57 are PCR primers useful in identification of RAGE 1. Detailed Description ofthe Invention An antigen recognized on a renal cell carcinoma by autologous CTL restricted by HLA-B7 is encoded by a previously unknown gene. This gene is silent in all normal tissues (including testis). except for retina and it is expressed in several tumor samples. EXAMPLE 1 : Description of an anti-renal cell carcinoma CTL clone of patient LE92U Tumor line LE9211-RCC is a renal cell carcinoma line derived from a tumor sample of a female patient named LE9211. A sample thereof was irradiated, so as to render it non-proliferative. These irradiated cells were then used to isolate cytolytic T cell clones ("CTLs") specific thereto. A sample of peripheral blood mononuclear cells ("PBMCs") was taken from patient LE 9211. and contacted to the irradiated carcinoma cells. After 14 days, the mixture was observed for lysis ofthe carcinoma cells, which indicated that CTLs specific for a complex of peptide and HLA molecule presented by the carcinoma cells were present in the sample. The lysis assay employed was a chromium release assay following Herin et al.. Int. J. Cancer 39:390- 396 (1987). The assay, however, is briefly described herein. The target carcinoma cells were grown in vitro. and then resuspended at 10 7 cells/ml in Dulbecco's Modified Eagles Medium (DMEM). supplemented with 30% FCS. and incubated for 45 minutes at 37°C with 200 μCi/ml of Na( 51 Cr)O 4 . Labeled cells were washed three times with DMEM. These were then resuspended in DMEM supplemented with 10 mM Hepes and 10% fetal calf serum (FCS), after which 100 μl aliquots containing 10 3 cells were distributed into 96 well microplates. Samples of lymphocytes were added in 100 μl ofthe same medium, and assays were carried out in duplicate. Plates were centrifuged for 4 minutes at 100g and incubated for four hours at 37°C in a 8% CO 2 atmosphere. Plates were centrifuged again, and 100 μl aliquots of supernatant were collected and counted. Percentage of 5l Cr release was calculated as follows: % 5l Cr release = fER-SRI x 100 (MR-SR) where ER is observed, experimental 5l Cr release. SR is spontaneous release measured by incubating 10 3 labeled cells in 200 μl of medium alone, and MR is maximum release, obtained by adding 100 μl 0.3% Triton X-100 to target cells. Those mononuclear blood samples which showed high CTL activity were expanded and cloned λ ia limiting dilution, and were screened again- using the same methodology . A first CTL clone was then isolated. The clone is referred to as 263/17 hereafter. A second CTL clone. 361 A/17. was obtained similarly from the same experiment and was used as described further below when CTL 263/17 failed to grow indefinitle\ . CTL clones 263/17 and 361 A/17 were capable of lysing specifically the autologous tumor cells and not NK-target K562 cells. NK - target K562 cells are available from the ATCC. Rockville. Maryland. CTL clone 263/17 produced TNF when stimulated with the autologous tumor cells. To identify the HLA molecule that presented the antigen to CTL clone 263/17. inhibition experiments were carried out where the production of TNF was tested in the presence of monoclonal antibodies directed against HLA molecules or against CD4/CD8 accessoiy molecules. Four monoclonal antibodies were found to inhibit the production of TNF by CTL 263/17: ( 1 ) monoclonal antibody W6/32. which is directed against all HLA class I molecules (Paiham et al.. 1979, J. Immunol.. 123 :342); (2) antibody B 1.23.2 which recognizes HLA-B and C molecules (Rebai et al., 1983. Tissue Antigens, 22:107); (3) antibody ME-1 which specifically recognizes HLA-B7 (Ellis et al.. 1982. Hum. Immunol.5:49); and (4) antibody B9.4.1 against CD8. No inhibition was found with antibodies directed against HLA Class II DR molecules (L243: Lampson et al.. 1980. J. Immunol. 125:293). against HLA-A3 (GAPA 3 : Berger et al.. 1982 Hybridoma 1 :87) or against CD4 ( 13B.8.82). The conclusion was that CTL 263/17 was ofthe CD8 type, and recognized an antigen presented by HLA-B7. To define the tumor specificity of this CTL clone, normal kidney cells derived from another patient which are also HLA-B7 (PTEC-HLA-B7 cells) were tested. These cells derive from the proximal tubular epithelium which is the site of origin of renal cell carcinoma PTEC-HLA-B7 cells were not lysed by the CTL. suggesting that the antigen is specifically expressed on tumors. Renal cell carcinoma line MZ-1851. which is derived from another HLA-B7 patient was also lysed by the CTL. showing that the antigen is shared by independent tumors. EXAMPLE 2: Isolation of a cDNA clone that directs the expression ofthe antigen recognized bv CTL 263/17 A. cDNA library RNA was isolated from LE-9211-RCC. and poly-A " RNA was purified by oligo-dT binding. cDNA was prepared by reverse transcription with an oligo-dT primer containing a Not I site, followed by second strand synthesis (Superscript Choice System. BRL. Life Technologies). The cDNA was then ligated to a BstXl adaptor, digested with Not I, size-fractionated (Sephaciyl S-500 HR columns. BRL. Life Technologies) and cloned unidirectionally into the BstXl and Not 1 sites of pcDNA-I-Amp (Invitrogen). The recombinant plasmid was then electroporated into DH5 £ coli bacteria. 1500 pools of 100 recombinant bacteria were amplified and plasmid DNA of each pool was extracted by alkaline lysis, potassium acetate precipitation and phenol extraction. B . Transfection of COS cells Plasmid DNA from the different pools was co-transfected into COS cells with 60 ng ofthe HLA-B7 cDNA (cloned by PCR from the cDNA of another HLA-B7 patient and inserted into plasmid vector pcDSRalpha). The transfection was made in duplicate wells. Briefly, samples of COS-7 cells were seeded, at 15,000 cells/well into tissue culture flat bottom microwells, in DMEM supplemented with 10% fetal calf serum. The cells were incubated overnight at 37°C. medium was removed and then replaced by 50 μl/well of DMEM medium containing 10% Nu-Serum (Collaborative Research, Bedford, MA).400μg/ml DEAE- dextran, and 100 μM chloroquine, plus 100 ng ofthe plasmids. Following four hours of incubation at 37°C. the medium was removed, and replaced by 50 μl of PBS containing 10% dimethyl sulfoxide (DMSO). This medium was removed after two minutes and replaced by 200 μl of DMEM supplemented with 10% FCS. Following this change in medium, COS cells were incubated for 24-48 hours at 37°C. The transfectants then were screened with CTL 263/17. After first removing the medium. 3000 CTL 263/17 cells were added to each well in 1 OOμl of medium containing 25 U/ml IL-2. The amount of TNF present in the supernatant was then measured by testing its cytotoxicity for WEHI 164.13 cells. Most pools gave a TNF concentration below 10 pg ml. Two pools (1157 and 1319) gave higher concentrations in both ofthe duplicate wells (24 to 37 pg/ml). The bacteria of pool 1319 were cloned and 1200 clones were obtained. Their plasmid DNA was extracted and transfected into COS cells with HLA-B7. The transfectants were screened with CTL 263/17. One cDNA clone (9H3) gave a high TNF production by CTL 263/17. Figure 1 shows the result obtained when this cDNA (60 ng) was transfected into COS cells with the HLA-B7 cDNA (60 ng) and screened with CTL 263/17. This cDNA also was stably transfected into LB23-SAR cells, an HLA-B7 sarcoma line. The lysis test then was performed with CTL clone 361 A/17, which recognizes the same antigen as CTL clone 263/17. These stably transfected cells were recognized in the same manner as the COS-HLA-B7-cDNA 9H3 cells. EXAMPLE 3: Sequence of cDNA 9H3 cDNA clone 9H3 is 1 130 bp long. This cDNA was not complete because its size was smaller than that of an mRNA observed on a Northern blot ( 1.6kb). The 5' end ofthe cDNA was cloned by RACE-PCR and the entire sequence was confirmed. This entire sequence is shown as SEQ.ID.NO.1. A comparison with the sequences reported in databanks showed at the 3' end a high homology with a short sequence of 235 bp called "expressed sequence tag", whose function is unknown (I), and at the 5' end a limited homology (75% in a stretch of 95 bases) with the antisense strand of two human endogenous retroviruses called RTVL-H2 and RGH2 (2. 3). The gene was called RAGE, for Renal tumor AntiGEn. The sequence contains five open reading frames. ORF1 : 99 base pairs encoding a protein of 32 residues; ORF2: 123 base pairs encoding a protein of 40 residues; ORF3: 87 base pairs encoding a protein of 28 residues; ORF4: 288 base pairs encoding a protein of 95 residues; and ORF5: 222 base pairs encoding a protein of 73 residues. (SEQ.ID.NOs.2, 4, 6, 8 and 10. respectively). SEQ.ID.NO.4 codes for the TRAP from which the antigenic peptide reactive with CTL 263/17 (as an HLA-B7/peptide complex) is derived. EXAMPLE 4: Identification of Additional RAGE Genes This example describes the identification of three additional RAGE genes and the determination that only the RAGE gene identified in the above examples, now designated RAGE- 1. encodes a RAGE TRA reactive with CTL 263/17. A probe was prepared from RAGE-1 cDNA and used to screen a LE9211-RCC cDNA library for additional RAGE genes. Three cDNAs homologous to RAGE, labeled RAGE-2 (SEQ.ID.NO.12). RAGE-3 (SEQ.ID.NO.13) and RAGE (SEQ.ID.NO.14). were isolated. The RAGE-2.3 and 4 genes were sequenced by standard methods. Comparison ofthe nucleotide seαuences of these RAGE cDNAs with the RAGE- 1 cDN A showed that truncated and novel open reading frames (ORFs) were present in the newly identified RAGE cDNAs. RAGE-2, RAGE-3 and RλGE-4 contained an insert of 37 bp at position 249 of RAGE1 (within the sequence corresponding to ORF2 (SEQ.ID.NO.4) of RAGE-1 ). For the RAGE-2 cDNA. comparison with the cosmid sequence indicated that this insertion corresponds to the beginning of an exon. Its absence from the RAGE-1 cDNA might result from the use of an alternative downstream acceptor site. In addition. RAGE-2. 3 and 4 differ from RAGE-1 in lacking a nucleotide at position 1 2 of RAGE- 1. These changes significanth modify the ORFs of RAGE-2.3 and 4 that are homologous to ORF2 and 3 of RAGE- 1. In addition. RAGE-3 has another insertion of 47 bp at the 5' end. Except for these differences, the RAGE-1.2 and 3 sequences are identical. RAGE-4 is about 800 bp longer than the other RAGE cDNAs. Its 5' sequence is identical to that of RAGE-2. but from position 434 to the poly-A tail the RAGE sequence differs totally from the other RAGE cDNAs. The RAGE-4 cDNA was shown not to be chimeric. The starting position ofthe 3' unrelated sequence corresponds to an exon-intron boundry in the RAGE genomic sequence, and the 3' unrelated sequence was present in the 3' end ofthe RAGE gene. Therefore, the RAGE cDNA appears to result from differential splicing ofthe RAGE-2 gene. The schematic alignment ofthe four cDNAs is shown in Fig. 2. There are 17 ORFs in the four RAGE cDNAs. Of these 17. 10 are different The ORFs are as follows: Gene ORF Nucleotide No. SEQ.ID.NO. RAGE-1 ORF1 173-271 2 ORF2 204-326 4 ORF3 313-399 6 ORF4 323-610 8 ORF5 444-665 10 RAGE-2 ORF2' 217-276 15 ORF3' 273449 17 ORF4 373-660 19 ORF5 494-715 21 RAGE-3 ORF6 185-247 23 ORF2' 274-333 25 ORF3' 330-506 27 ORF4 430-717 29 ORF5 551-772 31 RAGE4 ORF2' 213-272 JO ORF3" 269-832 35 ORF4' 369-557 37 The RAGE-2 . RAGE-3 and RAGE-4 cDNAs were cloned into expression plasmids by art-standard procedures and transfected as described with HLA-B7 into COS-7 cells to determine if these cDNAs also encoded the antigen recognized by CTL 263/17. Parallel control experiments with the RAGE cDNA (now referred to as RAGE- 1 ) and with LE9211 -RCC cells were also performed. Incubation of LE9211-RCC cells or COS-7 cells cotransfected with RAGE-1 and HLA-B7 with CTL 263/17 strongly induced release of WF by CTL 263/17. Cotransfection of RAGE-2. RAGE-3 or RAGE4 and HLA-B7 did not elicit TNF release. Therefore, only RAGE-1 was able to transfer expression ofthe antigen recognized by CTL 263/17. EXAMPLE 5: Identification of ORF containing RAGE tumor rejection antigen The 37 bp insertion in RAGE-2. 3 and 4 caused premature termination of ORF2 in these three genes. It was reasoned, therefore, that the antigenic peptide recognized by CTL 263/17 was encoded by the 3' end of ORF2. To test this hypothesis, the DNA sequences corresponding to ORF2 of RAGE 1 and ORF2' of RAGE-2 and RAGE-3 were cloned into an expression vector and transfected into COS-7 cells with HLA-B7 as described above. As positive controls, the RAGE-1 cDNA was cotransfected with HLA-B7 into COS-7 cells or LE2911 -RCC cells were used. These transfectants or LE2911 -RCC cells were used to provoke release of TNF from CTL 263/17 cells. Among the ORF transfectants. only the ORF2 from RAGE-1 successfully stimulated TNF release from CTL 263/17 cells (Fig. 3). This experiment confirmed that the RAGE antigenic peptide recognized by CTL 263/17 cells was encoded by the 3' end of ORF2 of RAGE-1. EXAMPLE 6: Identification of RAGE tumor rejection antigen peptide Synthetic peptides corresponding to the 3' end of RAGE-1 ORF2 were synthesized and tested for stimulation of TNF release from CTL 263/17 cells. COS-7 cells were transfected with HLA-B7 as described above and a synthetic peptide corresponding to a 3' portion of ORF2 was added to the culture. CTL 263/17 cells were added and the production of TNF was measured after 18 hours (Fig.4). Peptide SPSSNRIRNTST (SEQ.ID.NO.39) efficiently stimulated the release of TNF fom CTL 263/17. Since peptides presented by HLA class I molecules are usually 9 amino acids in length, we tested nonameric peptides (SEQ.ID.NOs.40, 41 and 42) derived from the dodecameric peptide (SEQ.ID.NO.39) previously used to stimulate TNF release from CTL 263/17 cells. The results of these experiments are shown in Fig.4. One of these peptides (SPSSNRIRN, SEQ.ID.NO.40) was recognized by CTL 263/17, but to a far lesser extent than the dodecameric peptide, which suggested that the nonamer (SEQ.ID.NO.40) was not the optimal peptide. The decameric peptide (SPSSNRIRNT, SEQ.ID.NO.43) was very efficiently recognized by CTL 263/17. EXAMPLE 7: Activity of RAGE tumor rejection antigen nonamer and decamer peptides This example shows the ability ofthe RAGE TRA peptide to induce lysis of HLA-B7-expressing cells and the relative efficiencies ofthe nonamer and decamer peptides. Nonameric and decameric RAGE peptides (SEQ.ID.NOs.40 and 43. respectively) were tested for the ability to induce cell lysis of HLA-B7 * LB23-EBV B cells by CTL 263/17 cells in a dose response assay. Lyophilized peptides were dissolved at 20 mg/ml in DMSO. then diluted to 2 mg/ml in lOmM acetic acid and stored at -80°C. Target cells, HLA-B7 ^ EBV-transformed lymphoblastoid cells (LB23-EBV cells), were labeled with 5l Cr. as described above, for 1 hour at 37°C followed by extensive washing to remove unincorporated label. LB23-EBV cells were then incubated in 96-well microplates in the presence of various concentrations of peptides for 30 minutes at 37°C. CTL263/17 were then added in an equal volume of medium at an effectoπtarget ratio of 10: 1. Chromium-51 release was measured after 4 hours. Fig. 5 shows the results of the dose response assay. Half maximal lysis ofLB23-EBV cells was induced at a concentration of 30 ng/ml SPSSNRIRNT peptide (SEQ.ID.NO.43). EXAMPLE 8: Expression of RAGE-1 gene The expression of RAGE was tested by PCR using the following primers: SEQ.ID.NO.46 - GTG TCT CCT TCG TCT CTA CTA (sense primer) SEQ.ID.NO.47 - GGT GTG CCG ATG ACA TCG (antisense primer common to all RAGE genes) SEQ.ID.NO.48 - GAG GTA TTC CTG ATC CTG (antisense primer specific for RAGE-1 ) First total RNA was taken from the particular sample, using art recognized techniques. This RNA was used to prepare cDNA. The protocol used to make the cDNA involved combining 4 μl of 5x reverse transcriptase buffer, 1 μl of each dNTP (lOmM), 2 μl of dithiothreitol (lOOmM), 2 μl of dT-15 primer (20 μM), 0.5 μl of RNasin (40 units/μl). and 1 μl of M-MLV reverse transcriptase (200 units/μl). Next 6.5 μl of template RNA (1 μg/3.25 μl water, or 2 μg total template RNA) was added. The total volume ofthe mixture was 20 μl. This was mixed and incubated at 42°C for 60 minutes, after which it was chilled on ice. A total of 80 μl of water was then added, to 100 μl total. This mixture was stored at -20°C until used in PCR. The reagents for PCR included: 5 microliters of 1 Ox DynaZyme buffer 20 pmoles of each primer 5 nanomoles of each dNTP - 1 unit of polymerizing enzyme "Dynazyme" (2 units/μl) 5 μl of cDNA (corresponding to 100 ng total RNA) water to a final volume of 50 μl The mixture was combined and layered with one drop of mineral oil. The mixture was transferred to a thermocycler block, preheated to 94°C, and amplification was carried out for one cycle of 15 min at 94°C. followed by 33 cycles of: l min. at 94°C 2 min. at 56°C or 60°C (see below) 3 min. at 72°C A final extension step of 15 min. was then performed at 72°C. Expression of all RAGE genes was tested b\ PCR amplification with pan-RAGE sense (SEQ.ID.NO.46) and antisense (SEQ.ID .NO.47) primers using an annealing step of 60°C for 2 minutes. Expression of only RAGE-1 gene was tested by PCR amplification with pan-RAGE sense (SEQ.ID.NO.46) and RAGE- 1 -specific antisense (SEQ.ID.NO.48) primers using an - 18 annealing step of 56°C for 2 minutes. The PCR product of 194 base pairs (general to all RAGE genes tested) and 239 base pairs (specific for RAGE-1 genes) were visualized on an agarose gel ( 1.5%) containing ethidium bromide. The gene was found to be tumor-specific. The gene was silent in all normal tissues tested, except for retina In particular, the gene was silent in adrenals, bladder, bone marrow, brain, breast cerebellum, colon- heart kidney, liver, lung, melanocytes, muscle, nevus, ovary, placenta, prostate, skia splenocytes. stomach. testis, thymocytes. uterus and healing wounds. The gene, however, was found to be expressed in a variety of tumor cell lines and tumor tissue samples (Table 1 ). It is also expressed in some other tumors which are not listed here, although not frequently. Table 1. Expression of RAGE- 1 Gene in Tumor Samples Histological Type Number of Tumors Expressing ALL RAGE RAGE-1 Tumor Samples Renal carcinoma 2/57 1/57 Sarcomas 5/25 3^5 Bladder tumors superficial -0/29 0/29 infiltrating -3/37 3/37 Melanomas primary lesions -260 2/60 metastases -8/177 6/177 Head and neck tumors 2/50 1/50 Mammary carcinomas 3/128 1/128 Prostatic carcinomas 0/22 0/22 Colorectal carcinomas 0/48 0/48 Leukemias 0/19 0/19 Lung carcinomas (NSCLC 1 ) 0/59 0/59 (SCLC) 0/5 0/5 Mesotheliomas 1/3 0/3 Brain tumors 0/11 0/11 Oesophage tumors 0/7 0/7 Ovarian tumors 0/3 0/3 Tumor Cell Lines Renal carcinoma 8/19 7/19 Bladder tumors 3/3 3/3 Mesotheliomas 11/19 8/19 Head and neck tumors 3/7 1/7 Sarcomas 2/6 1/6 Melanomas 11/78 7/78 Colorectal carcinomas 1/17 1/17 Lung carcinomas (NSCLC 1 ) 02 0/2 (SCLC) 0/26 0/26 Leukemias/Lymphomas 0/11 0/11 Brain tumors 0/1 0/1 Gastric tumors 0/2 0/2 ' NSCLC: non-small cell lung carcinoma The foregoing examples show the isolation of a nucleic acid molecule which codes for a TRAP. This TRAP coding molecule, however, is not homologous with any ofthe previously disclosed coding sequences described in the references set forth supra. Hence, one aspect ofthe invention is an isolated nucleic acid molecule which includes all or a unique portion ofthe nucleotide sequence set forth in SEQ.ID.NO.1. SEQ.ED.NO.4. SEQ.ID.NO.6 or SEQ.ID.NO.10. It is also expected that antigens derived from other RAGE ORFs encoded by SEQ.ID.NOs. 12. 13 and 14 may be recognized cytolytic T lymphocyte clones other than CTL263/17. Thus, the invention in another aspect involves any one or more ofthe RAGE family of genes. including isolated unique portions thereof such as portions encoding TRAPs and TRAs, RAGE TRAPs and TRAs derived therefrom and all ofthe diagnostic and therapeutic modalities relating thereto. The foregoing sequences are not MAGE, BAGE or GAGE sequences, as will be seen by comparing them to the MAGE. BAGE or GAGE sequences described in the references. Also a part ofthe invention are those nucleic acid sequences which also code for a non-MAGE. non- BAGE and non-GAGE tumor rejection antigen precursor but which hybridize to a nucleic acid molecule consisting ofthe above described nucleotide sequences, under stringent conditions. The term "stringent conditions" as used herein refers to parameters with which the art is familiar. More specifically, stringent conditions, as used herein, refers to hybridization at 65°C in hybridization buffer (3.5 x SSC.0.02% Ficoll. 0.02% Polyvinyl pyrolidone.0.02% Bovine Serum Albumin.25mM NaH 2 P0 (pH7).0.5% SDS.2mM EDTA). SSC is 0.15M Sodium Chloride/0.15M Sodium Citrate. pH 7: SDS is Sodium dodecyl Sulphate: and EDTA is Ethylene diamine tetra acetic acid. After hybridization, the membrane upon which the DNA is transferred is washed al 2xSSC at room temperature and then at 0.1 xSSC/0.1 xSDS at 65°C. There are other conditions, reagents, and so forth which can be used, which result in the same degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. The skilled artisan also is familiar with the methodology for screening cells, preferably cancer cells, for expression of such molecules which then are routinely isolated, followed by isolation ofthe pertinent nucleic acid. In screening for RAGE family members, a Southern blot may be performed using the foregoing conditions, together with a 32 P probe. After washing the membrane to which the DNA was finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal. The invention thus provides isolated unique fragments of SEQ.ID.NO.1 or its complement. A unique fragment is one that is a 'signature' for RAGE genes. It for example, is long enough to assure that its precise sequence is not found in molecules outside ofthe RAGE family as defined by claim 23. Preferred unique fragments are those found only in ORF2 or its complement. Unique fragments can be used as probes in Southern blot assays to identify RAGE family members including those expressing ORF2 or can be used in amplification assays such as those employing PCR. As known to those skilled in the art large probes such as 200 bp or more are preferred for certain uses such as Southern blots, while smaller fragments will be preferred for uses such as PCR. As will be recognized by those skilled in the art the size of a unique fragment will depend upon its conservency in the genetic code. Thus, some regions of SEQ.ID.NO.1. SEQ.ID.NO.12. SEQ.ID.NO.13 and SEQ.ID.NO.14 will require longer segments to be unique while others will require only short segments, typically between 12 and 32 bp (e.g. 12, 13, 14. 15, 16. 17. 18. 19, 20.21.22.23.24.25.26. 27, 28, 29.30, 31 and/or 32 bases long). Virtually any segment of SEQ.ID.NO.1 that is 18 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis ofthe ability ofthe unique fragment to selectively distinguish the sequence of interest from nonfamily members. A comparison ofthe sequence ofthe fragment to those on known data bases typically is all that is necessary, although in vitro confirmatory hybridization and sequencing analysis may be performed. For any pair of PCR primers constructed and arranged to selectively amplify RAGE-1. a RAGE-1 specific primer may be used. Such a primer is a contiguous stretch of RAGE- 1 which hybridizes to both sides ofthe insertion point in ORF2 which is altered by the insertion of additional nucleotides in other RAGE genes. Such a specific primer would fully hybridize to a contiguous stretch of nucleotides only in RAGE- 1. but would hybridize only in part to RAGE genes that do not share ORF 2. For efficient PCR priming and RAGE 1 identificatioa the RAGE 1 specific primer should be constructed and arranged so it does not hybridize efficiently at its 3' end to RAGE genes other than RAGE 1. To accomplish this, the primer can be described as having two ends: a 5' end that is contiguous with and complementary to one side ofthe insertion point joined directly to a 3' end that is contiguous with and complementary to the opposite side ofthe insertion point. By making the 5' end ofthe primer substantially longer than the 3' end. and by making the 3' end short (i.e. 14 nucleotides), then the kinetics of hybridization will strongly favor hybridization at the 5' end. In this instance, 3' initiated PCR extension will occur only when both the 5' and 3' ends hybridize to the nucleic acid. i.e. only when ORF 2 is present without an insert RAGE-1 specific primers, as described above, may be designed to prime DNA synthesis on either strand ofthe DNA helix, described herein as the Watson or the Crick strands. The sequence in RAGE 1 which flanks the insertion point is 5'-CAAACANGGATCA-3' (SEQ.ID.NO.49; Watson strand. N is a nucleotide insert). A RAGE-1 specific primer designed to preferentially amplify the Watson strand of RAGE-1 typically would comprise 12 and preferably 15 or more nucleotides ary to the nucleotides ofthe Watson strand 3' to the insertion point. The remaining portion ofthe primer would be one to four nucleotides long and would be complementary to the sequence 5' to the insertion point. Such a primer would be perfectly complementary and contiguous with its complement in RAGE-1. The 3' end ofthe primer would hybridize to its complement in the Watson strand and initiate extension. In RAGE genes other than RAGE-1. the insertion of noncomplementary nucleotides at the insertion point of ORF2 would substantially eliminate hybridization ofthe 3' end ofthe RAGE-1 specific primer to the Watson strand 5' ofthe insert. The mismatch generated at the 3' end ofthe primer when hybridized to RAGE genes, other than RAGE- 1. would preclude efficient amplification of those genes. Exemplary primers consist essentially ofthe following sequences, wherein N is zero, one or more contiguous nucleotides on the appropriate Watson or Crick strands: 5'-NTATTCCTGATCCT-3'(SEQ.ID.NO. 50): 5'-NTATTCCTGATCCTG-3'(SEQ.ID.NO. 51 ); 5 , -NTATTCCTGATCCTGT-3'(SEQ.ID.NO. 52); 5'-NTATTCCTGATCCTGTT-3'(SEQ.ID.NO. 53); 5'-NCAAGTTCAAACAG-3'(SEQ.ID.NO. 54); 5'-NCAAGTTCAAACAGG-3'(SEQ.ID.NO. 55): 5'-NCAAGTTCAAACAGGA-3'(SEQ.ID.NO. 56); and 5'-NCAAGTTCAAACAGGAT-3'(SEQ.ID.NO. 57). The expression of RAGE- 1 may also be detected by PCR using primers which initiate extension on opposite sides ofthe insertion point. Analysis of amplification products can distinguish RAGE-1 amplification products from non-RAGE- 1 amplification products by the length ofthe amplification products. Because the RAGE-1 gene does not contain the insert present in other RAGE genes, amplification products derived from RAGE-1 will be shorter than amplification products derived from other RAGE genes (by about 37 base pairs). This difference may be distinguished readily using standard methods in the art. Additional methods which can distinguish nucleotide sequences of substantial homology, such as ligase chain rection ("LCR") and other methods, will be apparent to skilled artisans. RAGE 2. 3 and 4 specific primers may be prepared in a like manner. The invention also includes the use of nucleic acid sequences which include alternative codons that encode the same amino acid residues as encoded by the RAGE genes. For example, as disclosed above in Example 7. a decameric peptide SPSSNRIRNT (SEQ.ID.NO.43) is a RAGE tumor rejection antigen. The serine residues (amino acids No. 1.3 and 4 of SEQ.ID.NO .40) for example, are encoded by the codons TCA. AGT and TCA, respectively. In addition to TCA and AGT. serine amino acid residues may also be encoded by the codons TCC, TCG, TCT and AGC. Each ofthe six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any ofthe serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, in vitro or in vivo, to incorporate a serine residue. Similarly, nucleotide sequence triplets which encode other amino acid residues comprising a RAGE tumor rejection antigen include: CCA CCC. CCG and CCT (proline codons): CGA. CGC. CGG. CGT. AGA and AGG (aiginine codons); ACA ACC. ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy ofthe genetic code. The examples above also show the isolation of peptides which are RAGE TRAs. These exemplar.' peptides are processed translation products ofthe nucleic acids of SEQ.ID.NO.1. As such, it will be appreciated by one of ordinary skill in the art that the translation products from which a RAGE TRA is processed to a final form for presentation may be of any length or sequence so long as they encompass the RAGE TRA. As demonstrated in the examples above, peptides or proteins as small as 9. 10. or 12 amino acids and as large as the amino acid sequence encoded by ORF 1 are appropriately processed, presented by HLA-B7 and recognized by CTL263/17. The peptide of SEQ.ID.NO.23 may have one. two. three, four. five. six. seven, eight nine. ten. or more amino acids added to either or both ends. The antigenic portion of such a peptide is cleaved out under physiological conditions for presentation by HLA class I molecules. The amino acid sequence of proteins and peptides from which RAGE TRAs are derived may be of natural or non-natural origia that is. they may comprise a natural RAGE TRAP molecule or may comprise a modified sequence as long as the amino acid sequence retains the tumor rejection antigen sequence recognized by the CTL when presented on the surface of a cell. For example. RAGE tumor rejection antigens in this context may be fusion proteins of a RAGE tumor rejection antigen and unrelated amino acid sequences, the translated polypeptide of ORF2 ofthe RAGE-1 gene, synthetic peptides of amino acid sequences shown in SEQ.ID.NOs.39.40 and 43, labeled peptides, peptides isolated from patients with renal cell carcinoma peptides isolated from cultured cells which express RAGE-1. peptides coupled to nonpeptide molecules for example in certain drug delivery systems and other molecules which include the amino acid sequence of SEQ.ID.NO.40. It will also be seen from the examples that the invention embraces the use ofthe sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g.. £ colϊ). or eukaryotic (e.g.. CHO cells. COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). The expression vectors require that the pertinent sequence, i.e.. those described supra, be operably linked to a promoter. As it has been found that human HLA-B7 presents a TRA derived from these genes, the expression vector may also include a nucleic acid sequence coding for HLA-B7. In a situation where the vector contains both coding sequences, it can be used to transfect a cell which does not normally express either one. The TRAP or TRA coding sequence may be used alone, whea e.g. the host cell already expresses HLA-B7. Of course, there is no limit on the particular host cell which can be used. As the vectors which contain the two coding sequences may be used in HLA-B7 presenting cells if desired, and the nucleic acid coding for the TRAP or TRA can be used in host cells which do not express HLA-B7. The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of at least two ofthe previously discussed materials. Other components may be added, as desired. To distinguish the nucleic acid molecules and the TRAPs ofthe invention from the previously described MAGE family. BAGE gene and GAGE gene, the invention shall be referred to as the RAGE family of genes and TRAPs. Hence, whenever "RAGE" is used hereia specifically excluded are MAGE. BAGE and GAGE genes, gene products. TRAPs and TRAs. The invention as described herein has a number of uses, some of which are described herein. First the invention permits the artisan to diagnose a disorder characterized by expression ofthe TRAP. These methods involve determining expression ofthe TRAP gene, and/or TRAs derived therefrom, such as a TRA presented by HLA-B7. hi the former situatioa such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reactioa or assaying with labeled hybridization probes. In the latter situatioa assaying with binding partners for complexes of TRA and HLA such as antibodies, is especially preferred. An alternate method for determination is a TNF release assay, ofthe type described supra. The isolation ofthe TRAP gene also makes it possible to isolate the TRAP molecule itself, and/or TRAs derived therefrom, especially TRAP and/or TRA molecules containing the amino acid sequences coded for by SEQ.ID.NO! or4. Other TRAPs or TRAs encoded by SEQ.ID.NOs. 1, 12, B and 14 and recognized by other CTL clones and/or presented by other HLA molecules may be isolated by the procedures detailed herein. (There are numerous HLA molecules known to those skilled in the art, including but not limited to. those encoded by HLA-A HLA-B, HLA-C. HLA-E. HLA-F and HLA-G genes.) A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated TRAP molecules, and/or TRAs derived therefrom. The protein may be purified from cells which naturally produce the protein. Alternatively, an expression vector may be introduced into cells to cause production ofthe protein. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production ofthe encoded protein. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce protein. Peptides comprising TRAs ofthe invention may also be synthesized in vitro. Those skilled in the art also can readily follow known methods for isolating proteins in order to obtain isolated TRAP and or TRAs derived therefrom. These include, but are not limited to. immunochromotography. HPLC. size-exclusion chromatography. ion-exchange chromatography and immune-affinity chromatography. These isolated molecules when processed and presented as the TRA or as complexes of TRA and HLA such as HLA-B7. may be combined with materials such as adjuvants to produce vaccines useful in treating disorders characterized by expression ofthe TRAP molecule. In additioa vaccines can be prepared from cells which present the TRA/HLA complexes on their surface, such as non-proliferative cancer cells, non- proliferative transfectants. etcetera In all cases where cells are used as a vaccine, these can be cells transfected with coding sequences for one or both ofthe components necessary to provoke a CTL response, or be cells which already express both molecules without the need for transfection. Vaccines also encompass naked DNA or RNA encoding a RAGE TRA or precursor thereof, which may be produced in vitro and administered via injectioa particle bombardment nasal aspiration and other methods. Vaccines ofthe "naked nucleic acid" type have been demonstrated to provoke an immunological response including generation of CTLs specific for the peptide encoded by the naked nucleic acid (Science 259: 1745-1748. 1993). The TRAP molecule, its associated TRAs. as well as complexes of TRA and HLA. may be used to produce antibodies, using standard techniques well known to the art. Standard reference works setting forth the general principles of antibody production include Catty. D.. Antibodies. A Practical Approach. Vol. 1. IRL Press. Washington DC (1988 ; Kleia J- Immunology: The Science of Cell-Non-Cell Discriminatioa John Wiley and Sons. New Yoik (1982); Kennett R.. et al.. Monoclonal Antibodies. Hybridoma A Ne Dimension In Biological Analyses. Plenum Press. New York (1980); Campbell. A.. Monoclonal Antibody Technology, in Laboratory Techniques and Biochemistry and Molecular Biology. Vol. 13 (Burdoa R. et al. EDS.). Elsevier Amsterdam (1984); and Eisea H.N., Microbiology, third editioa Davis. B.D. et al. EDS. (Harper & Rowe, Philadelphia (1980). The antibodies ofthe present invention thus are prepared by any of a variety of methods, including administering protein, fragments of proteia cells expressing the protein or fragments thereof and the like to an animal to induce polyclonal antibodies. The production of monoclonal antibodies is according to techniques well known in the art. As detailed hereia such antibodies may be used for example to identify tissues expressing protein or to purify protein. Antibodies also may be coupled to specific labeling agents for imaging or to antitumor agents, including, but not limited to, methotrexate. radioiodinated compounds, toxins such as ricia other cytostatic or cytolytic drugs, and so forth. Antibodies prepared according to the invention also preferably are specific for the TRA/HLA complexes described herein. When "disorder" is used hereia it refers to any pathological condition where the tumor rejection antigen precursor is expressed. An example of such a disorder is cancer, renal cell carcinoma in particular. Some therapeutic approaches based upon the disclosure are premised on a response by a subject's immune system, leading to lysis of TRA presenting cells, such as HLA-B7 cells. One such approach is the administration of autologous CTLs specific to the complex to a subject with abnormal cells ofthe phenotype at issue. It is within the skill ofthe artisan to develop such CTLs in vitro. Generally, a sample of cells taken from a subject such as blood cells, are contacted with a cell presenting the complex and capable of provoking CTLs to proliferate. The target cell can be a transfectant such as a COS cell ofthe type described supra. These transfectants present the desired complex of their surface and. when combined with a CTL of interest stimulate its proliferation. COS cells, such as those used herein are widely available, as are other suitable host cells. Specific production of a CTL clone has been described above. The clonally expanded autologous CTLs then are administered to the subject. Other CTLs specific to RAGE-1 and CTLs specific to RAGE TRAs encoded by RAGE-2, 3, or 4 may be isolated and administered by similar methods. To detail atherapeutic methodology, referred to as adoptive transfer (Greenberg. J. Immunol. 136(5): 1917 (1986); Riddel et al.. Science 257: 238 (7-10-92): Lynch et al. Eur. J. Immunol.21: 1403-1410 (1991): Kast et al.. Cell 59: 603-614 (11-17-89)). cells presenting the desired complex are combined with CTLs leading to proliferation ofthe CILs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain ofthe abnormal cells presenting the particular complex. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal. The foregoing therapy assumes that at least some ofthe subject's abnormal cells present the relevant HLA/TRA complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expressing DNA of the pertinent sequences, in this case a RAGE sequence. Once cells presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient where the sample contains CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that a RAGE derived. TRA is being presented, and the subject is an appropriate candidate for the therapeutic approaches set forth supra. Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked in vivo, using a number of approaches. One approach, i.e.. the use of non- proliferative cells expressing the complex, has been elaborated upon supra. The cells used in this approach may be those that normally express the complex, such as irradiated tumor cells or cells transfected with one or both ofthe genes necessary for presentation ofthe complex. Chen et al.. Proc. Natl. Acad. Sci. USA 88: 110- 114 (January, 1991) exemplifies this approach, showing the use of transfected cells expressing HPVE7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred. For example, nucleic acids which encode a RAGE TRA may be operably linked to promoter and enhancer sequences which direct expresion ofthe RAGE TRA in certain tissues or cell types. The nucleic acid may be incorporated into an expression vector. Expression vectors may be unmodified extrachromosomal nucleic acids, plasmids or viral genomes constructed or modified to enable insertion of exogenous nucleic acids, such as those encoding RAGE TRAs. Nucleic acids encoding a RAGE TRA also may be inserted into a retroviral genome, thereby facilitating integration ofthe nucleic acid into the genome of tiie target tissue or cell type. In these systems, the gene of interest is carried by a microorganism, e.g.. a Vaccinia virus, retrovirus or the bacteria BCG. and the materials de facto "infect" host cells. The cells which result present the complex of interest and are recognized by autologous CTLs. which then proliferate. A similar effect can be achieved by combining the TRAP or a stimulatory fragment thereof with an adjuvant to facilitate incorporation into HLA-B7 presenting cells n vivo. The TRAP is processed to yield the peptide partner ofthe HLA molecule while the TRA is presented without the need for further processing. Generally, subjects can receive an intradermal injection of an effective amount ofthe RAGE TRAP, andor TRAs derived therefrom. Initial doses can be followed by booster doses, following immunization protocols standard in the art. As part ofthe immunization protocols, substances which potentiate the immune response may be administered with nucleic acid or peptide components of a cancer vaccine. Such immune response potentiating compound may be classified as either adjuvants or cytokines. Adjuvants may enhance the immunological response by providing a reservoir of antigen ( extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes. Adjuvants of many kinds are well known in the art; specific examples include MPL (SmithKline Beecham), a congener obtained after purification and acid hydrolysis of Salmonella minnesota Re 595 lipopolysaccharide, QS21 (SmithKline Beecham). a pure QA-21 saponin purified from Ouiilja saponaria extract and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol Cytokines are also useful in vaccination protocols as a result of lymphocyte stimulatory properties. Many cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-12) which has been shown to enhance the protective effects of vaccines (Science 268: 1432-1434. 1995). When administered, the therapeutic compositions ofthe present invention are administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents. The preparations ofthe invention are administered in effective amounts. An effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, stimulates the desired response. In the case of treating cancer, the desired response is inhibiting the progression ofthe cancer. This may involve only slowing the progression ofthe disease temporarily, although more preferably, it involves halting the progression ofthe disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods ofthe invention discussed herein. Where it is desired to stimulate an immune response using a therapeutic composition ofthe invention this may involve the stimulation of a humoral antibody response resulting in an increase in antibody liter in serum, a clonal expansion of cytotoxic lymphocytes, or some other desirable immunologic response. It is believed that doses of immunogens ranging from one nanogram/kilograrn to 100 miligrams/kilogram. depending upon the mode of administratioa would be effective. The preferred range is believed to be between 500 nanograms and 500 micrograms per kilogram. The absolute amount will depiend upon a variety of factors, including the material selected for administratioa whetlier the administration is in single or multiple doses, and individual patient parameters including age. physical condition size, weight and the stage ofthe disease. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. Other aspects ofthe invention will be clear to the skilled artisan and need not be repeated here. The terms and expressions which have been employed are used as terms of description and not of limitatioa and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope ofthe invention. References 1) Gleser, L.. and Swaroop, A. 1992. Expressed sequence tags and chromosomal localization of cDNA clones from a subtracted retinal pigment epithelium library. Genomics 13. 873-876. 2) Mager, D.. and Freemaa J D. 1987. Human endogenous retrovirus-like genome with Type C pol sequences and gag sequences related to human T-ceil lymphotropic viruses. J. Virol. 61.40604066. 3) Hirose. Y.. Takamatsu, M.. Harada F. 1993. Presence of env genes in members ofthe RTVL-H family of human endogenous retrovirus-like elements. Virology 192.52-61. Sequence Listing (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: LUDWIG INSTITUTE FOR CANCER RESEARCH (B) STREET:1345 Avenue of the Americas (C) CITY: New York (D) STATE: NEW YORK (E) COUNTRY: UNITED STATES OF AMERICA (F) ZIP: 10105 (i) APPLICANT: (A) NAME: LEIDEN UNIVERSITY (B) STREET: Stationsweg 46 (C) CITY: Leiden (E) COUNTRY: THE NETHERLANDS (F) ZIP: 2312 AV (ii) TITLE OF INVENTION: RAGE TUMOR REJECTION ANTIGENS (iii) NUMBER OF SEQUENCES: 57 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: WOLF, GREENFIELD & SACKS, P.C. (B) STREET: 600 ATLANTIC AVENUE (C) CITY: BOSTON (D) STATE: MASSACHUSETTS (E) COUNTRY: UNITED STATES OF AMERICA (F) ZIP: 02210 J - (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/401,015 (B) FILING DATE: 21-MAR-1995 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/530,569 (B) FILING DATE: 20-SEP-1995 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: GATES, EDWARD R. (B) REGISTRATION NUMBER: 31,616 (C) REFERENCE/DOCKET NUMBER: L0461/7002WO (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 617-720-3500 (B) TELEFAX: 617-720-2441 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1311 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: GGTGAGCAGC CAAAGCAGGC ATCCCCGCAG TTGACTTGCC ACCAAGGGAA TGTGGGTGAA 60 TGACCAAGGC AGGCATCCTC GCGGTGATCA GACACCAATG GAGTGTGGGT GAATAATCAG 120 GCAGGCATCC CCGCAGTGAT TAAACACCAA GAGAAGACTA TTCCTGAGTC TGTGACTGGT 180 GCTGGAGTTT TGAGTCCACA GATAAAATGT GTCTCCTTCG TCTCTACTAG AGAGGAAAAA 240 GAACTGGAAT TGGAAGAACA GGGAGACTGA AGGGTAGCAA GAGAGGCTGG AGAAGAGAGT 300 GAAAAGACCG CTTACCTGAT TTGAAATTGT CTGCAGCCCC TCTTTCCTGG AGTAAATGAA 360 CTGGACCAAA TCTCAAAAAA TCCACGATGT CATCGGCACA CCCGCTCAGA AGATCCTCAC 420 CAAGTTCAAA CAGGATCAGG AATACCTCTA CTAACAACCA ATTTGTCCCC ACAATGCCTC 480 - ol - TCCCTCCTGC ACGCAATGGT GGCCTATGAT CCCGATGAGA GAATCGCCGC CCACCAGGCC 540 CTGCAGCACC CCTACTTCCA AGAACAGAGA AACAGTCCCT AAAGCAAGAG GAGGACCGTC 600 CCAAGAGACG AGGACCGGCC TATGTCATGG AACTGCCCAA ACTAAAGCTT TCGGGAGTGG 660 TCAGACTGTC GTCTTACTCC AGCCCCACGC TGCAGTCCGT GCTTGGATCT GGAACAAATG 720 GAAGAGTGCC GGTGCTGAGA CCCTTGAAGT GCATCCCTGC GAGCAAGAAG ACAGATCCGC 780 AGAAGGACCT TAAGCCTGCC CCGCAGCAGT GTCGCCTGCC CACCATAGTG CGGAAAGGCG 840 GAAGATAACT GAGCAGCACC GTCGTCTCGA CTTCGGAGGC AACACCAAGC CCGACCGGGC 900 CAGGCCTGGG TGATCTGCTG CTGAGACGCC ACGGAGGGCT GGGGATGCGC CTGCGTCCGT 960 TTCGCGCTGG CCGGGGCTCT GGGTGCTGCC CTGCGCCCTG CCGCACCCGC GGCCCGCGCA 1020 GCTGCCTAGG ATGTTCTGGG CTAATATACT TGTAAAACCA CCGCATTCTA GGGTTTTCTT 1080 TCATTTTCGT TAAGAATTTG GGGCAGGAAA TACTTTGTAA CTTTGTATAT GAATCAAAAC 1140 AAACGAGCAG GCATTTCTGT GATGTGTTGG GCGTGGTTGG AAGGTGGGTT CTGCGTGTCC 1200 CTTCCCAGCG CTGCTGGTCA GTCGTGGAGC GCCATCATGT CTTACCAGTG ACGCTGCTGA 1260 CACCCCTGAC TTTTATTAAA GAATAAGCTG TCGTTAAAAA AAAAAAAAAA A 1311 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: - _ - (A) LENGTH: 99 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..99 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: ATG AAC TGG ACC AAA TCT CAA AAA ATC CAC GAT GTC ATC GGC ACA CCC 48 Met Asn Trp Thr Lys Ser Gin Lys lie His Asp Val lie Gly Thr Pro 1 5 10 15 GCT CAG AAG ATC CTC ACC AAG TTC AAA CAG GAT CAG GAA TAC CTC TAC 96 Ala Gin Lys lie Leu Thr Lys Phe Lys Gin Asp Gin Glu Tyr Leu Tyr 20 25 30 TAA 99 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 Met Asn Trp Thr Lys Ser Gin Lys He His Asp Val He Gly Thr Pro 1 5 10 15 Ala Gin Lys He Leu Thr Lys Phe Lys Gin Asp Gin Glu Tyr Leu Tyr 20 25 30 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 123 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..123 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: ATG TCA TCG GCA CAC CCG CTC AGA AGA TCC TCA CCA AGT TCA AAC AGG 48 Met Ser Ser Ala His Pro Leu Arg Arg Ser Ser Pro Ser Ser Asn Arg 1 5 10 15 ATC AGG AAT ACC TCT ACT AAC AAC CAA TTT GTC CCC ACA ATG CCT CTC 96 He Arg Asn Thr Ser Thr Asn Asn Gin Phe Val Pro Thr Met Pro Leu 20 25 30 CCT CCT GCA CGC AAT GGT GGC CTA TGA 123 Pro Pro Ala Arg Asn Gly Gly Leu 35 40 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Met Ser Ser Ala His Pro Leu Arg Arg Ser Ser Pro Ser Ser Asn Arg 1 5 10 15 He Arg Asn Thr Ser Thr Asn Asn Gin Phe Val Pro Thr Met Pro Leu 20 25 30 Pro Pro Ala Arg Asn Gly Gly Leu 35 40 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 87 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAQVENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..87 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: ATG GTG GCC TAT GAT CCC GAT GAG AGA ATC GCC GCC CAC CAG GCC CTG 48 Met Val Ala Tyr Asp Pro Asp Glu Arg He Ala Ala His Gin Ala Leu 1 5 10 15 CAG CAC CCC TAC TTC CAA GAA CAG AGA AAC AGT CCC TAA 87 Gin His Pro Tyr Phe Gin Glu Gin Arg Asn Ser Pro 20 25 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Met Val Ala Tyr Asp Pro Asp Glu Arg He Ala Ala His Gin Ala Leu 1 5 10 15 Gin His Pro Tyr Phe Gin Glu Gin Arg Asn Ser Pro 20 25 - _>o - (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 288 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..288 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: ATG ATC CCG ATG AGA GAA TCG CCG CCC ACC AGG CCC TGC AGC ACC CCT 48 Met He Pro Met Arg Glu Ser Pro Pro Thr Arg Pro Cys Ser Thr Pro 1 5 10 15 ACT TCC AAG AAC AGA GAA ACA GTC CCT AAA GCA AGA GGA GGA CCG TCC 96 Thr Ser Lys Asn Arg Glu Thr Val Pro Lys Ala Arg Gly Gly Pro Ser 20 25 30 CAA GAG ACG AGG ACC GGC CTA TGT CAT GGA ACT GCC CAA ACT AAA GCT 144 Gin Glu Thr Arg Thr Gly Leu Cys His Gly Thr Ala Gin Thr Lys Ala 35 40 45 TTC GGG AGT GGT CAG ACT GTC GTC TTA CTC CAG CCC CAC GCT GCA GTC 192 Phe Gly Ser Gly Gin Thr Val Val Leu Leu Gin Pro His Ala Ala Val 50 55 60 CGT GCT TGG ATC TGG AAC AAA TGG AAG AGT GCC GGT GCT GAG ACC CTT 240 Arg Ala Trp He Trp Asn Lys Trp Lys Ser Ala Gly Ala Glu Thr Leu 65 70 75 80 GAA GTG CAT CCC TGC GAG CAA GAA GAC AGA TCC GCA GAA GGA CCT TAA 288 Glu Val His Pro Cys Glu Gin Glu Asp Arg Ser Ala Glu Gly Pro 85 90 95 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 95 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Met He Pro Met Arg Glu Ser Pro Pro Thr Arg Pro Cys Ser Thr Pro 1 5 10 15 Thr Ser Lys Asn Arg Glu Thr Val Pro Lys Ala Arg Gly Gly Pro Ser 20 25 30 Gin Glu Thr Arg Thr Gly Leu Cys His Gly Thr Ala Gin Thr Lys Ala 35 40 45 Phe Gly Ser Gly Gin Thr Val Val Leu Leu Gin Pro His Ala Ala Val 50 55 60 Arg Ala Trp He Trp Asn Lys Trp Lys Ser Ala Gly Ala Glu Thr Leu 65 70 75 80 Glu Val His Pro Cys Glu Gin Glu Asp Arg Ser Ala Glu Gly Pro 85 90 95 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 222 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..222 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: ATG GAA CTG CCC AAA CTA AAG CTT TCG GGA GTG GTC AGA CTG TCG TCT 48 Met Glu Leu Pro Lys Leu Lys Leu Ser Gly Val Val Arg Leu Ser Ser 1 5 10 15 TAC TCC AGC CCC ACG CTG CAG TCC GTG CTT GGA TCT GGA ACA AAT GGA 96 Tyr Ser Ser Pro Thr Leu Gin Ser Val Leu Gly Ser Gly Thr Asn Gly 20 25 30 AGA GTG CCG GTG CTG AGA CCC TTG AAG TGC ATC CCT GCG AGC AAG AAG 144 Arg Val Pro Val Leu Arg Pro Leu Lys Cys He Pro Ala Ser Lys Lys 35 40 45 ACA GAT CCG CAG AAG GAC CTT AAG CCT GCC CCG CAG CAG TGT CGC CTG 192 Thr Asp Pro Gin Lys Asp Leu Lys Pro Ala Pro Gin Gin Cys Arg Leu 50 55 60 CCC ACC ATA GTG CGG AAA GGC GGA AGA TAA 222 Pro Thr He Val Arg Lys Gly Gly Arg 65 70 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 73 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Met Glu Leu Pro Lys Leu Lys Leu Ser Gly Val Val Arg Leu Ser Ser 1 5 10 15 Tyr Ser Ser Pro Thr Leu Gin Ser Val Leu Gly Ser Gly Thr Asn Gly 20 25 30 Arg Val Pro Val Leu Arg Pro Leu Lys Cys He Pro Ala Ser Lys Lys 35 40 45 Thr Asp Pro Gin Lys Asp Leu Lys Pro Ala Pro Gin Gin Cys Arg Leu 50 55 60 Pro Thr He Val Arg Lys Gly Gly Arg 65 70 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1168 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: CTGTGACTGG TGCTGGAGTT TTGAGTCCAC AGATAAAATG TGTCTCCTTC GTCTCTACTA 60 GAGAGGAAAA AGAACTGGAA TTGGAAGAAC AGGGAGACTG AAGGGTAGCA AGAGAGGCTG 120 GAGAAGAGAG TGAAAAGACC GCTTACCTGA TTTGAAATTG TCTGCAGCCC CTCTTTCCTG 180 GAGTAAATGA ACTGGACCAA ATCTCAAAAA TCCACGATGT CATCGGCACA CCCGCTCAGA 240 AGATCCTCAC CAAGTTCAAA CAGTCGAGAG CTATGAATTT TGATTTTCCT TTTAAAAAGG 300 GATCAGGAAT ACCTCTACTA ACAACCAATT TGTCCCCACA ATGCCTCTCC CTCCTGCACG 360 CAATGGTGGC CΓATGATCCC GATGAGAGAA TCGCCGCCCA CCAGGCCCTG CAGCACCCCT 420 ACTTCCAAGA ACAGAGAAAC AGTCCCTAAA GCAAGAGGAG GACCGTCCCA AGAGACGAGG 480 ACCGGCCTAT GTCATGGAAC TGCCCAAACT AAAGCTTTCG GGAGTGGTCA GACTGTCGTC 540 TTACTCCAGC CCCACGCTGC AGTCCGTGCT TGGATCTGGA ACAAATGGAA GAGTGCCGGT 600 GCTGAGACCC TTGAAGTGCA TCCCTGCGAG CAAGAAGACA GATCCGCAGA AGGACCTTAA 660 GCCTGCCCCG CAGCAGTGTC GCCTGCCCAC CATAGTGCGG AAAGGCGGAA GATAACTGAG 720 CAGCACCGTC GTCTCGACTT CGGAGGCAAC ACCAAGCCCG ACCGGGCCAG GCCTGGGTGA 780 TCTGCTGCTG AGACGCCACG GAGGGCTGGG GATGCGCCTG CGTCCGTTTC GCGCTGGCCG 840 GGGCTCTGGG TGCTGCCCTG CGCCCTGCCG CACCCGCGGC CCGCGCAGCT GCCTAGGATG 900 TTCTGGGCTA ATATACTTGT AAAACCACCG CATTCTAGGG TTTTCTTTCA TTTTCGTTAA 960 GAATTTGGGG CAGGAAATAC TTTGTAACTT TGTATATGAA TCAAAACAAA CGAGCAGGCA 1020 TTTCTGTGAT GTGTTGGGCG TGGTTGGAAG GTGGGTTCTG CGTGTCCCTT CCCAGCGCTG 1080 CTGGTCAGTC GTGGAGCGCC ATCATGTCTT ACCAGTGACG CTGCTGACAC CCCTGACTTT 1140 TATTAAAGAA TAAGCTGTCG TTAAAAAA 1168 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1235 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: ATTCCTGAGT CTGTGACTGG TGCTGGAGTT TTGAGTCCAC AGATAAAATG TGTCTCCTTC 60 GTCTCTACTA GAGAGGAAAA AGAACTGGAA TTGGAAGAAC AGGGAGACTG AAGGGTAGCA 120 AGAGAGGCTG GAGAAGAGAG TGAAAAGACC GCTTACCTGA TTTGAAATTG ATGGTGGCGT 180 GGGAATGAAG AATGTGATAT ACATCTTTGG AGTCTGTTCT GCAGCCCCTC TTTCCTGGAG 240 TAAATGAACT GGACCAAATC TCAAAAATCC ACGATGTCAT CGGCACACCC GCTCAGAAGA 300 TCCTCACCAA GTTCAAACAG TCGAGAGCTA TGAATTTTGA TTTTCCTTTT AAAAAGGGAT 360 CAGGAATACC TCTACTAACA ACCAATTTGT CCCCACAATG CCTCTCCCTC CTGCACGCAA 420 TGGTGGCCTA TGATCCCGAT GAGAGAATCG CCGCCCACCA GGCCCTGCAG CACCCCTACT 480 TCCAAGAACA GAGAAACAGT CCCTAAAGCA AGAGGAGGAC CGTCCCAAGA GACGAGGACC 540 GGCCTATGTC ATGGAACTGC CCAAACTAAA GCTTTCGGGA GTGGTCAGAC TGTCGTCTTA 600 CTCCAGCCCC ACGCTGCAGT CCGTGCTTGG ATCTGGAACA AATGGAAGAG TGCCGGTGCT 660 GAGACCCTTG AAGTGCATCC CTGCGAGCAA GAAGACAGAT CCGCAGAAGG ACCTTAAGCC 720 TGCCCCGCAG CAGTGTCGCC TGCCCACCAT AGTGCGGAAA GGCGGAAGAT AACTGAGCAG 780 CACCGTCGTC TCGACTTCGG AGGCAACACC AAGCCCGACC GGGCCAGGCC TGGGTGATCT 840 GCTGCTGAGA CGCCACGGAG GGCTGGGGAT GCGCCTGCGT CCGTTTCGCG CTGGCCGGGG 900 CTCTGGGTGC TGCCCTGCGC CCTGCCGCAC CCGCGGCCCG CGCAGCTGCC TAGGATGTTC 960 TGGGCTAATA TACTTGTAAA ACCACCGCAT TCTAGGGTTT TCTTTCATTT TCGTTAAGAA 1020 TTTGGGGCAG GAAATACTTT GTAACTTTGT ATATGAATCA AAACAAACGA GCAGGCATTT 1080 CTGTGATGTG TTGGGCGTGG TTGGAAGGTG GGTTCTGCGT GTCCCTTCCC AGCGCTGCTG 1140 GTCAGTCGTG GAGCGCCATC ATGTCTTACC AGTGACGCTG CTGACACCCC TGACTTTTAT 1200 TAAAGAATAA GCTGTCGTTA CAGTATTGCA AAAAA 1235 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2051 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: GACTGGTGCT GGAGTTTTGA GTCCACAGAT AAAATGTGTC TCCTTCGTCT CTACTAGAGA 60 GGAAAAAGAA CTGGAATTGG AAGAACAGGG AGACTGAAGG GTAGCAAGAG AGGCTGGAGA 120 AGAGAGTGAA AAGACCGCTT ACCTGATTTG AAATTGTCTG CAGCCCCTCT TTCCTGGAGT 180 AAATGAACTG GACCAAATCT CAAAAATCCA CGATGTCATC GGCACACCCG CTCAGAAGAT 2 0 CCTCACCAAG TTCAAACAGT CGAGAGCTAT GAATTTTGAT TTTCCTTTTA AAAAGGGATC 300 AGGAATACCT CTACTAACAA CCAATTTGTC CCCACAATGC CTCTCCCTCC TGCACGCAAT 360 GGTGGCCTAT GATCCCGATG AGAGAATCGC CGCCCACCAG GCCCTGCAGC ACCCCTACTT 420 CCAAGAACAG AGAACCCAGA ACGGAAGCGA GGATGAAGGC CTCAGCCGTC CTCCTCCCCA 480 TTCAAACACG TTCATCCCTC AACCCTCTGC TGAGCACCTG CATGCTGCCC GGCCGCAGTG 540 TCACCCTTCT TGTGTGAGCC TACCCTCATC CACCCACCTC ACCCTCCTGA CCTTAAAGAA 600 GACACCGGGC AGAAGCACAG GGGAGCCCAG TCACACCCCA CACTGGCGGG GGCAGGCCTT 660 GCAGGGAGAA GCAGTAAGCA GCCATCTCCA TCAGCCATTT CCATCTGGCA CTCAGACGTG 720 CACGTCTTCG TGTGACAGGC GGCAGCAGTG CGACCGTGAC CTCCCATCTG CTCTGCTGTC 780 CCCACACCTG CGGTGCAGCC AGCCTGCCAC AAGGCAGCTA GAGTCCAGCT AGACCCACCC 840 CTGGCACGGC CGACCTCTTC CTGGCTTCTT CTGGGCCTAA TCCCCGTGCA TTCTCCAACG 900 CCAGAAGTGT AAGAAAGTGC AAGGCAACAA GTGAGAAGAG CAAACCCAAA TCGTACCAGG 960 GAAGCTAGTC TTTCCAGGGC ACCTGAGTGA GGGCATGACC AGCCTTGACG CTGCCTCGCT 1020 ACCATCTGCC CAGGGCCTGC TGAATGCTTG AGTCCATGGT GACAGTGGTG GGAACAGTTA 1080 CGAGGCAGTT AGATTTTGGA AGTCATGTTG GCCCACTTGG CTACAGAGCA GTCTTAGGAA 1140 CAGCACCATA AAAATAAAGA CTTATTCCTG ACACACATGC ATCTAGAGTA AACTGGGGCG 1200 TATCTGACAG CGTTAGTACA GTGATGGCCA AATGCAAACT GCATTCCAGA ACCAGCGAAG 1260 GGTGACAGAC TGGGCTGAGG CAGAGCTAGG ACTAACCATC TCGAGTGATG CCATCTCGGG 1320 GCCAACAAAA GTTTTGGACA CGGCTGGATC ATCTGACCAA ACTGCTCAAA TCTTTACACA 1380 ATTATTGTCC TGGTATTAAA CTTTCACCTG CCACTTCCAA CAAACAGGAG ACAGAATAAG 1440 GAGATGACCA GGAAGATGGC TGGATTAAGA ATTCTAGACT TGGCCGGGTG CGGTGGCTCA 1500 CACCTGTAAT CCTAGCATCT TGGGAGGCTG AGGCAGGAGG ATCGCTTGAG CCCAGAGTTT 1560 GAGACCAGCC TAGGCAACAT AAGGAGACCC CATCTCTACA AAATATCAAA AAATTACCCA 1620 GGTATGGTGG CACACACGTG TGATTCCAGC TACTCGGGAG GCTGAGATGG GAGGATCACT 1680 TGAACCCAGG AGGTTGGGGC TACAATGAGC TATGATCGCA CCACTTCATT CCAGCCTGGA 1740 TGACAGAAGA CTCACTCCAT AGTTCATGGC CCCGTGATCC AGAGTCCCTG CTGGCGCCTT 1800 CGAGTGGGGC AGGCTGAGAA CTCAAGCTGT AACTAATGTC TCCTCCGAAG AAAACTAAAC 1860 CGAGGGCTGA GCTGATGTGA AGTTTTCCGT GGCTGCATTC ATACAAATGG TGAAAATGTA 1920 GCATACCTCC CCTCAAAAGC CTGAAAGTAA AGACATGCCC CCAATTTAAT GTGATGAATT 1980 AGAGAAATAG GTTTCAGACA CTTCATGGTT TAAAGTCTCA CAAAATAAAG CTTTCGAAGG 2040 AAAAAAAAAA A 2051 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: ATG TCA TCG GCA CAC CCG CTC AGA AGA TCC TCA CCA AGT TCA AAC AGT 8 Met Ser Ser Ala His Pro Leu Arg Arg Ser Ser Pro Ser Ser Asn Ser 1 5 10 15 CGA GAG CTA TGA 60 Arg Glu Leu (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Met Ser Ser Ala His Pro Leu Arg Arg Ser Ser Pro Ser Ser Asn Ser 1 5 10 15 Arg Glu Leu (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 177 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..177 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: ATG AAT TTT GAT TTT CCT TTT AAA AAG GGA TCA GGA ATA CCT CTA CTA 48 Met Asn Phe Asp Phe Pro Phe Lys Lys Gly Ser Gly He Pro Leu Leu 1 5 10 15 ACA ACC AAT TTG TCC CCA CAA TGC CTC TCC CTC CTG CAC GCA ATG GTG 96 Thr Thr Asn Leu Ser Pro Gin Cys Leu Ser Leu Leu His Ala Met Val 20 25 30 GCC TAT GAT CCC GAT GAG AGA ATC GCC GCC CAC CAG GCC CTG CAG CAC 144 Ala Tyr Asp Pro Asp Glu Arg He Ala Ala His Gin Ala Leu Gin His 35 40 45 CCC TAC TTC CAA GAA CAG AGA AAC AGT CCC TAA 177 Pro Tyr Phe Gin Glu Gin Arg Asn Ser Pro 50 55 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Met Asn Phe Asp Phe Pro Phe Lys Lys Gly Ser Gly He Pro Leu Leu 1 5 10 15 Thr Thr Asn Leu Ser Pro Gin Cys Leu Ser Leu Leu His Ala Met Val 20 25 30 Ala Tyr Asp Pro Asp Glu Arg He Ala Ala His Gin Ala Leu Gin His 35 40 45 Pro Tyr Phe Gin Glu Gin Arg Asn Ser Pro 50 55 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 288 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..288 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: ATG ATC CCG ATG AGA GAA TCG CCG CCC ACC AGG CCC TGC AGC ACC CCT 48 Met He Pro Met Arg Glu Ser Pro Pro Thr Arg Pro Cys Ser Thr Pro 1 5 10 15 ACT TCC AAG AAC AGA GAA ACA GTC CCT AAA GCA AGA GGA GGA CCG TCC 96 Thr Ser Lys Asn Arg Glu Thr Val Pro Lys Ala Arg Gly Gly Pro Ser 20 25 30 CAA GAG ACG AGG ACC GGC CTA TGT CAT GGA ACT GCC CAA ACT AAA GCT 144 Gin Glu Thr Arg Thr Gly Leu Cys His Gly Thr Ala Gin Thr Lys Ala 35 40 45 TTC GGG AGT GGT CAG ACT GTC GTC TTA CTC CAG CCC CAC GCT GCA GTC 192 Phe Gly Ser Gly Gin Thr Val Val Leu Leu Gin Pro His Ala Ala Val 50 55 60 CGT GCT TGG ATC TGG AAC AAA TGG AAG AGT GCC GGT GCT GAG ACC CTT 240 Arg Ala Trp He Trp Asn Lys Trp Lys Ser Ala Gly Ala Glu Thr Leu 65 70 75 80 GAA GTG CAT CCC TGC GAG CAA GAA GAC AGA TCC GCA GAA GGA CCT TAA 288 Glu Val His Pro Cys Glu Gin Glu Asp Arg Ser Ala Glu Gly Pro 85 90 95 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 95 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Met He Pro Met Arg Glu Ser Pro Pro Thr Arg Pro Cys Ser Thr Pro 1 5 10 15 Thr Ser Lys Asn Arg Glu Thr Val Pro Lys Ala Arg Gly Gly Pro Ser 20 25 30 Gin Glu Thr Arg Thr Gly Leu Cys His Gly Thr Ala Gin Thr Lys Ala 35 40 45 Phe Gly Ser Gly Gin Thr Val Val Leu Leu Gin Pro His Ala Ala Val 50 55 60 Arg Ala Trp He Trp Asn Lys Trp Lys Ser Ala Gly Ala Glu Thr Leu 65 70 75 80 Glu Val His Pro Cys Glu Gin Glu Asp Arg Ser Ala Glu Gly Pro 85 90 95 (2) INFORMATION FOR SEQ ID NO:21: - JO - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 222 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..222 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: ATG GAA CTG CCC AAA CTA AAG CTT TCG GGA GTG GTC AGA CTG TCG TCT 48 Met Glu Leu Pro Lys Leu Lys Leu Ser Gly Val Val Arg Leu Ser Ser 1 5 10 15 TAC TCC AGC CCC ACG CTG CAG TCC GTG CTT GGA TCT GGA ACA AAT GGA 96 Tyr Ser Ser Pro Thr Leu Gin Ser Val Leu Gly Ser Gly Thr Asn Gly 20 25 30 AGA GTG CCG GTG CTG AGA CCC TTG AAG TGC ATC CCT GCG AGC AAG AAG 144 Arg Val Pro Val Leu Arg Pro Leu Lys Cys He Pro Ala Ser Lys Lys 35 40 45 ACA GAT CCG CAG AAG GAC CTT AAG CCT GCC CCG CAG CAG TGT CGC CTG 192 Thr Asp Pro Gin Lys Asp Leu Lys Pro Ala Pro Gin Gin Cys Arg Leu 50 55 60 CCC ACC ATA GTG CGG AAA GGC GGA AGA TAA 222 Pro Thr He Val Arg Lys Gly Gly Arg 65 70 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 73 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Met Glu Leu Pro Lys Leu Lys Leu Ser Gly Val Val Arg Leu Ser Ser 1 5 10 15 Tyr Ser Ser Pro Thr Leu Gin Ser Val Leu Gly Ser Gly Thr Asn Gly 20 25 30 Arg Val Pro Val Leu Arg Pro Leu Lys Cys He Pro Ala Ser Lys Lys 35 40 45 - 5o - Thr Asp Pro Gin Lys Asp Leu Lys Pro Ala Pro Gin Gin Cys Arg Leu 50 55 60 Pro Thr He Val Arg Lys Gly Gly Arg 65 70 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 63 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..63 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: ATG AAG AAT GTG ATA TAC ATC TTT GGA GTC TGT TCT GCA GCC CCT CTT 48 Met Lys Asn Val He Tyr He Phe Gly Val Cys Ser Ala Ala Pro Leu 1 5 10 15 TCC TGG AGT AAA TGA 63 Ser Trp Ser Lys 20 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Met Lys Asn Val He Tyr He Phe Gly Val Cys Ser Ala Ala Pro Leu 1 5 10 15 Ser Trp Ser Lys 20 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid - oU - (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: ATG TCA TCG GCA CAC CCG CTC AGA AGA TCC TCA CCA AGT TCA AAC AGT 48 Met Ser Ser Ala His Pro Leu Arg Arg Ser Ser Pro Ser Ser Asn Ser 1 5 10 15 CGA GAG CTA TGA 60 Arg Glu Leu (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Met Ser Ser Ala His Pro Leu Arg Arg Ser Ser Pro Ser Ser Asn Ser 1 5 10 15 Arg Glu Leu (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 177 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGYENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..177 (xi ) SEQUENCE DESCRIPTION: SEQ ID NO : 27 : ATG AAT TTT GAT TTT CCT TTT AAA AAG GGA TCA GGA ATA CCT CTA CTA 48 Met Asn Phe Asp Phe Pro Phe Lys Lys Gly Ser Gly He Pro Leu Leu 1 5 10 15 ACA ACC AAT TTG TCC CCA CAA TGC CTC TCC CTC CTG CAC GCA ATG GTG 96 Thr Thr Asn Leu Ser Pro Gin Cys Leu Ser Leu Leu His Ala Met Val 20 25 30 GCC TAT GAT CCC GAT GAG AGA ATC GCC GCC CAC CAG GCC CTG CAG CAC 144 Ala Tyr Asp Pro Asp Glu Arg He Ala Ala His Gin Ala Leu Gin His 35 40 45 CCC TAC TTC CAA GAA CAG AGA AAC AGT CCC TAA 177 Pro Tyr Phe Gin Glu Gin Arg Asn Ser Pro 50 55 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: amino acid - 03 - (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Met Asn Phe Asp Phe Pro Phe Lys Lys Gly Ser Gly He Pro Leu Leu 1 5 10 15 Thr Thr Asn Leu Ser Pro Gin Cys Leu Ser Leu Leu His Ala Met Val 20 25 30 Ala Tyr Asp Pro Asp Glu Arg He Ala Ala His Gin Ala Leu Gin His 35 40 45 Pro Tyr Phe Gin Glu Gin Arg Asn Ser Pro 50 55 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 288 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..288 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: ATG ATC CCG ATG AGA GAA TCG CCG CCC ACC AGG CCC TGC AGC ACC CCT 48 Met He Pro Met Arg Glu Ser Pro Pro Thr Arg Pro Cys Ser Thr Pro 1 5 10 15 ACT TCC AAG AAC AGA GAA ACA GTC CCT AAA GCA AGA GGA GGA CCG TCC 96 Thr Ser Lys Asn Arg Glu Thr Val Pro Lys Ala Arg Gly Gly Pro Ser 20 25 30 CAA GAG ACG AGG ACC GGC CTA TGT CAT GGA ACT GCC CAA ACT AAA GCT 144 Gin Glu Thr Arg Thr Gly Leu Cys His Gly Thr Ala Gin Thr Lys Ala 35 40 45 TTC GGG AGT GGT CAG ACT GTC GTC TTA CTC CAG CCC CAC GCT GCA GTC 192 Phe Gly Ser Gly Gin Thr Val Val Leu Leu Gin Pro His Ala Ala Val 50 55 60 CGT GCT TGG ATC TGG AAC AAA TGG AAG AGT GCC GGT GCT GAG ACC CTT 240 Arg Ala Trp He Trp Asn Lys Trp Lys Ser Ala Gly Ala Glu Thr Leu 65 70 75 80 GAA GTG CAT CCC TGC GAG CAA GAA GAC AGA TCC GCA GAA GGA CCT TAA 288 Glu Val His Pro Cys Glu Gin Glu Asp Arg Ser Ala Glu Gly Pro 85 90 95 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 95 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Met He Pro Met Arg Glu Ser Pro Pro Thr Arg Pro Cys Ser Thr Pro 1 5 10 15 Thr Ser Lys Asn Arg Glu Thr Val Pro Lys Ala Arg Gly Gly Pro Ser 20 25 30 Gin Glu Thr Arg Thr Gly Leu Cys His Gly Thr Ala Gin Thr Lys Ala 35 40 45 Phe Gly Ser Gly Gin Thr Val Val Leu Leu Gin Pro His Ala Ala Val 50 55 60 Arg Ala Trp He Trp Asn Lys Trp Lys Ser Ala Gly Ala Glu Thr Leu 65 70 75 80 - oo - Glu Val His Pro Cys Glu Gin Glu Asp Arg Ser Ala Glu Gly Pro 85 90 95 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 222 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..222 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: ATG GAA CTG CCC AAA CTA AAG CTT TCG GGA GTG GTC AGA CTG TCG TCT 48 Met Glu Leu Pro Lys Leu Lys Leu Ser Gly Val Val Arg Leu Ser Ser 1 5 10 15 TAC TCC AGC CCC ACG CTG CAG TCC GTG CTT GGA TCT GGA ACA AAT GGA 96 Tyr Ser Ser Pro Thr Leu Gin Ser Val Leu Gly Ser Gly Thr Asn Gly 20 25 30 AGA GTG CCG GTG CTG AGA CCC TTG AAG TGC ATC CCT GCG AGC AAG AAG 144 Arg Val Pro Val Leu Arg Pro Leu Lys Cys He Pro Ala Ser Lys Lys 35 40 45 ACA GAT CCG CAG AAG GAC CTT AAG CCT GCC CCG CAG CAG TGT CGC CTG 192 Thr Asp Pro Gin Lys Asp Leu Lys Pro Ala Pro Gin Gin Cys Arg Leu 50 55 60 CCC ACC ATA GTG CGG AAA GGC GGA AGA TAA 222 Pro Thr He Val Arg Lys Gly Gly Arg 65 70 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 73 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: - oo - Met Glu Leu Pro Lys Leu Lys Leu Ser Gly Val Val Arg Leu Ser Ser 1 5 10 15 Tyr Ser Ser Pro Thr Leu Gin Ser Val Leu Gly Ser Gly Thr Asn Gly 20 25 30 Arg Val Pro Val Leu Arg Pro Leu Lys Cys He Pro Ala Ser Lys Lys 35 40 45 Thr Asp Pro Gin Lys Asp Leu Lys Pro Ala Pro Gin Gin Cys Arg Leu 50 55 60 Pro Thr He Val Arg Lys Gly Gly Arg 65 70 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE : internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: ATC TCA TCG GCA CAC CCG CTC AGA AGA TCC TCA CCA AGT TCA AAC AGT 48 Met Ser Ser Ala His Pro Leu Arg Arg Ser Ser Pro Ser Ser Asn Ser 1 5 10 15 CGA GAG CTA TGA 60 Arg Glu Leu (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: Met Ser Ser Ala His Pro Leu Arg Arg Ser Ser Pro Ser Ser Asn Ser 1 5 10 15 Arg Glu Leu (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 564 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..564 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: ATC AAT TTT GAT TTT CCT TTT AAA AAG GGA TCA GGA ATA CCT CTA CTA 48 Met Asn Phe Asp Phe Pro Phe Lys Lys Gly Ser Gly He Pro Leu Leu 1 5 10 15 ACA ACC AAT TTG TCC CCA CAA TGC CTC TCC CTC CTG CAC GCA ATG GTC 96 Thr Thr Asn Leu Ser Pro Gin Cys Leu Ser Leu Leu His Ala Met Val 20 25 30 GCC TAT GAT CCC GAT GAG AGA ATC GCC GCC CAC CAG GCC CTG CAG CAC 144 Ala Tyr Asp Pro Asp Glu Arg He Ala Ala His Gin Ala Leu Gin His 35 40 45 CCC TAC TTC CAA GAA CAG AGA ACC CAG AAC GGA AGC GAG GAT GAA GGC 192 Pro Tyr Phe Gin Glu Gin Arg Thr Gin Asn Gly Ser Glu Asp Glu Gly 50 55 60 CTC AGC CGT CCT CCT CCC CAT TCA AAC ACG TTC ATC CCT CAA CCC TCT 240 Leu Ser Arg Pro Pro Pro His Ser Asn Thr Phe He Pro Gin Pro Ser 65 70 75 80 GCT GAG CAC CTG CAT GCT GCC CGG CCG CAG TGT CAC CCT TCT TGT GTG 288 Ala Glu His Leu His Ala Ala Arg Pro Gin Cys His Pro Ser Cys Val 85 90 95 AGC CTA CCC TCA TCC ACC CAC CTC ACC CTC CTG ACC TTA AAG AAG ACA 336 Ser Leu Pro Ser Ser Thr His Leu Thr Leu Leu Thr Leu Lys Lys Thr 100 105 110 CCG GGC AGA AGC ACA GGG GAG CCC AGT CAC ACC CCA CAC TGG CGG GGG 384 Pro Gly Arg Ser Thr Gly Glu Pro Ser His Thr Pro His Trp Arg Gly 115 120 125 CAG GCC TTC CAG GGA GAA GCA GTA AGC AGC CAT CTC CAT CAG CCA TTT 432 Gin Ala Leu Gin Gly Glu Ala Val Ser Ser His Leu His Gin Pro Phe 130 135 140 CCA TCT GGC ACT CAG ACG TGC ACG TCT TCG TCT GAC AGG CGG CAG CAG 480 Pro Ser Gly Thr Gin Thr Cys Thr Ser Ser Cys Asp Arg Arg Gin Gin 145 150 155 160 TGC GAC CGT GAC CTC CCA TCT GCT CTC CTG TCC CCA CAC CTG CGG TGC 528 Cys Asp Arg Asp Leu Pro Ser Ala Leu Leu Ser Pro His Leu Arg Cys 165 170 175 AGC CAG CCT GCC ACA AGG CAG CTA GAG TCC AGC TAG 564 Ser Gin Pro Ala Thr Arg Gin Leu Glu Ser Ser 180 185 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 187 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: Met Asn Phe Asp Phe Pro Phe Lys Lys Gly Ser Gly He Pro Leu Leu 1 5 10 15 Thr Thr Asn Leu Ser Pro Gin Cys Leu Ser Leu Leu His Ala Met Val 20 25 30 Ala Tyr Asp Pro Asp Glu Arg He Ala Ala His Gin Ala Leu Gin His 35 40 45 Pro Tyr Phe Gin Glu Gin Arg Thr Gin Asn Gly Ser Glu Asp Glu Gly 50 55 60 Leu Ser Arg Pro Pro Pro His Ser Asn Thr Phe He Pro Gin Pro Ser 65 70 75 80 Ala Glu His Leu His Ala Ala Arg Pro Gin Cys His Pro Ser Cys Val 85 90 95 Ser Leu Pro Ser Ser Thr His Leu Thr Leu Leu Thr Leu Lys Lys Thr 100 105 110 Pro Gly Arg Ser Thr Gly Glu Pro Ser His Thr Pro His Trp Arg Gly 115 120 125 Gin Ala Leu Gin Gly Glu Ala Val Ser Ser His Leu His Gin Pro Phe 130 135 140 Pro Ser Gly Thr Gin Thr Cys Thr Ser Ser Cys Asp Arg Arg Gin Gin 145 150 155 160 Cys Asp Arg Asp Leu Pro Ser Ala Leu Leu Ser Pro His Leu Arg Cys 165 170 175 Ser Gin Pro Ala Thr Arg Gin Leu Glu Ser Ser 180 185 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 189 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..189 (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 37 : ATG ATC CCG ATG AGA GAA TCG CCG CCC ACC AGG CCC TGC AGC ACC CCT Met He Pro Met Arg Glu Ser Pro Pro Thr Arg Pro Cys Ser Thr Pro 1 5 10 15 ACT TCC AAG AAC AGA GAA CCC AGA ACG GAA GCG AGG ATG AAG GCC TCA 96 Thr Ser Lys Asn Arg Glu Pro Arg Thr Glu Ala Arg Met Lys Ala Ser 20 25 30 GCC GTC CTC CTC CCC ATT CAA ACA CGT TCA TCC CTC AAC CCT CTG CTG 144 Ala Val Leu Leu Pro He Gin Thr Arg Ser Ser Leu Asn Pro Leu Leu 35 40 45 AGC ACC TGC ATG CTG CCC GGC CGC AGT GTC ACC CTT CTT GTG TGA 189 Ser Thr Cys Met Leu Pro Gly Arg Ser Val Thr Leu Leu Val 50 55 60 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 62 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: Met He Pro Met Arg Glu Ser Pro Pro Thr Arg Pro Cys Ser Thr Pro 1 5 10 15 Thr Ser Lys Asn Arg Glu Pro Arg Thr Glu Ala Arg Met Lys Ala Ser 20 25 30 - lb - Ala Val Leu Leu Pro He Gin Thr Arg Ser Ser Leu Asn Pro Leu Leu 35 40 45 Ser Thr Cys Met Leu Pro Gly Arg Ser Val Thr Leu Leu Val 50 55 60 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 39 : Ser Pro Ser Ser Asn Arg He Arg Asn Thr Ser Thr 1 5 10 (2 ) INFORMATION FOR SEQ ID NO : 40 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: Ser Pro Ser Ser Asn Arg He Arg Asn 1 5 (2) INFORMATION FOR SEQ ID NO:41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO - t o - (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: Pro Ser Ser Asn Arg He Arg Asn Thr 1 5 (2) INFORMATION FOR SEQ ID NO:42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: Ser Ser Asn Arg He Arg Asn Thr Ser 1 5 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: Ser Pro Ser Ser Asn Arg He Arg Asn Thr 1 5 10 (2) INFORMATION FOR SEQ ID NO:44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: TCACCAAGTT CAAACAGGAT CAGGAAT 27 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: TCACCAAGTT CAAACAGGAT CAGGAATACC 30 (2) INFORMATION FOR SEQ ID NO:46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46 GTGTCTCCTT CGTCTCTACT A 21 (2) INFORMATION FOR SEQ ID NO:47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: YES (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47: GGTGTGCCGA TGACATCG 18 (2) INFORMATION FOR SEQ ID NO:48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: YES (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: GAGGTATTCC TGATCCTG 18 (2) INFORMATION FOR SEQ ID NO:49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: CAAACANGGA TCA 13 (2) INFORMATION FOR SEQ ID NO:50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50: NTATTCCTGA TCCT 14 (2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY : linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51 NTATTCCTGA TCCTG 15 (2) INFORMATION FOR SEQ ID NO:52 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO - 00 - (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52: NTATTCCTGA TCCTGT 16 (2) INFORMATION FOR SEQ ID NO:53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53: NTATTCCTGA TCCTGTT 17 (2) INFORMATION FOR SEQ ID NO:54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: YES (v) FRAGYENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54: NCAAGTTCAA ACAG 14 (2) INFORMATION FOR SEQ ID NO:55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY : linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: YES (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: NCAAGTTCAA ACAGG 15 (2) INFORMATION FOR SEQ ID NO:56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE : YES (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: NCAAGTTCAA ACAGGA 16 (2) INFORMATION FOR SEQ ID NO:57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: YES (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: NCAAGTTCAA ACAGGAT 17

Claims: CLAIMS 1. An isolated polypeptide comprising the amino acid sequence of SEQ.ID.NO.40. 2. The isolated polypeptide of claim 1 wherein the isolated polypeptide comprises the amino acid sequence of SEQ.ID.NO.43. 3. The isolated polypeptide of claim 1 wherein the isolated polypeptide consists essentially of an amino acid sequence selected from the group consisting of SEQ.ID.NO.40 and SEQ.ID.NO.43. 4. The isolated polypeptide of claim 1 wherein the isolated polypeptide consists of an amino acid sequence selected from the group consisting of SEQ.ID.NO.40 and SEQ.ID.NO.43. 5. An isolated nucleic acid encoding a polypeptide selected from the group consisting ofthe polypeptide of claim 1, the polypeptide of claim 2. the polypeptide of claim 3 and the polypeptide of claim 4. 6. The isolated nucleic acid of claim 5 wherein the nucleic acid comprises SEQ.ID.NO.44. 7. An expression vector comprising the isolated nucleic acid of claim 5 operably linked to a promoter. 8. The expression vector of claim 7 wherein the nucleic acid comprises SEQ.ID.NO.44. 9. The expression vector of claims 7 or 8 further comprising a nucleic acid which codes for HLA-B7. 10. A host cell transfected or transformed with an expression vector selected from the group consisting ofthe expression vector of claim 7. the expression vector of claim 8 and the expression vector of claim 9. 1 1. A host cell transfected or transformed with an expression vector selected from the group ofthe expression vector of claim 7 and the expression vector of claim 8, and wherein the host cell expresses HLA-B7. 12. A kit for detecting the presence ofthe expression of a tumor rejection antigen precursor comprising: a first primer selected from the group consisting of a nucleic acid consisting essentially of any one of SEQ.ID.NOs.50-57. and a second primer constructed and arranged to selectively amplify together with the first primer a portion of ORF2 characteristic only of RAGE 1 genes. 13. A method for enriching selectively a population of T cells with cytolytic T cells specific for a RAGE tumor rejection antigen comprising: contacting an isolated population of T cells with an agent presenting a complex of a RAGE tumor rejection antigen and HLA presenting molecule in an amount sufficient to selectively enrich said isolated population of T cells with said cytolytic T cells. 14. The method of claim 13 wherein the HLA presenting molecule is HLA-B7 and wherein the RAGE tumor rejection antigen is selected from the group consisting of: a peptide consisting of the amino acids of SEQ. ID. NO.40 and a peptide consisting ofthe amino acids of SEQ.ID.NO.43. 15. A method for diagnosing a disorder characterized by expression of a RAGE tumor rejection antigen peptide. comprising: contacting a biological sample isolated from a subject with an agent that is specific for the RAGE tumor rejection antigen peptide. and determining the interaction between the agent and the RAGE tumor rejection antigen peptide as a determination ofthe disorder. 16. The method of claim 15 wherein the peptide is selected from the group consisting of: a peptide consisting ofthe amino acids of SEQ.ID.NO.40 and a peptide consisting ofthe amino acids of SEQ.ID.NO.43. 17. A method for diagnosing a disorder characterized by expression of a RAGE tumor rejection antigen peptide which forms a complex with HLA-B7 molecules, comprising: contacting a biological sample isolated from a subject with an agent that binds the complex; and determining binding between the complex and the agent as a determination ofthe disorder. 18. The method of claim 17 wherein the peptide is selected from the group consisting of: a peptide consisting of the amino acids of SEQ.ID.NO.40 and a peptide consisting ofthe amino acids of SEQ.ID.NO.43. 19. A method for treating a subject with a disorder characterized by expression of a RAGE tumor rejection antigen, comprising: administering to the subject an amount of an agent which enriches selectively in the subject the presence of complexes of HLA-B7 and RAGE tumor rejection antigen, sufficient to ameliorate the disorder. 20. The method of claim 1 wherein the RAGE tumor rejection antigen is selected from the group consisting of: a peptide consisting ofthe amino acids of SEQ.ID.NO.40 and a peptide consisting ofthe amino acids of SEQ.ID .NO.43. 21. A method for treating a subject with a disorder characterized by expression of a RAGE tumor rejection antigen, comprising: administering to the subject an amount of autologous cytolytic T cells sufficient to ameliorate the disorder, the cytolytic T cells specific for complexes of an HLA-B7 molecule and a RAGE tumor rejection antigen. 22. The method of claim 21 wherein the RAGE tumor rejection antigen is selected from the group consisting of: a peptide consisting ofthe amino acids of SEQ.ID.NO.40 and a peptide consisting ofthe amino acids of SEQ.ID.NO.43. 23. An isolated nucleic acid molecule which (a) hybridizes, under stringent conditions, to a molecule consisting ofthe nucleic acid sequence selected from the group consisting of: SEQ.ID.NO. 1 ; SEQ.ID.NO. 4; SEQ.ID.NO. 6; SEQ.ID.NO. 10; SEQ.ID.NO. 12; SEQ.ID.NO. 13; SEQ.ID.NO. 14; SEQ.ID.NO. 15: SEQ.ID.NO. 17; SEQ.ID.NO. 23; and/or SEQ.ID.NO. 35, and which codes for a tumor rejection antigen precursor, with the proviso that the isolated nucleic acid molecule does not code for a MAGE. GAGE, BAGE tumor rejection antigen precursor; and (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy ofthe genetic code. 24. The isolated nucleic acid molecule of claim 23 wherein the isolated nucleic acid molecule is a cDNA molecule or an mRNA molecule. 25. The isolated nucleic acid molecule of claim 23 wherein the isolated nucleic acid molecule codes for a tumor rejection antigen precursor coded for by a molecule having a sequence selected from the group consisting of SEQ.ID.NO. 1. SEQ.ID.NO. 12: SEQ.ID.NO. 13; and/or SEQ.ID.NO. 14. 26. The isolated nucleic acid molecule of claim 23 wherein the isolated nucleic acid molecule comprises a nucleic acid molecule that is complementary to nucleotides selected from the group consisting of: 204 to 326 of SEQ.ID.NO. 1: 313 to 399 of SEQ.ID.NO. 1; 444 to 665 of SEQ.ID.NO. 1; 273 to 449 of SEQ.ID.NO. 12; 217 to 276 of SEQ.ID.NO. 12; 185 to 247 of SEQ.ID.NO. 13; and/or 269 to 832 of SEQ.ID.NO. 14. 27. An isolated nucleic acid molecule consisting essentially of a nucleotide sequence selected from the group consisting of: SEQ.ID.NO. 1 ; SEQ.ID.NO. 4; SEQ.ID.NO. 6; SEQ.ID.NO. 10; SEQ.ID.NO. 12; SEQ.ID.NO. 13; SEQ.ID.NO. 14: SEQ.ID.NO. 15; SEQ.ID.NO. 17; SEQ.ID.NO. 23, SEQ.ID.NO. 35 and/or SEQ.ID.NO.45. 28. An expression vector comprising the isolated nucleic acid molecule of claims 23, 24. 25, 26 or 27, operably linked to a promoter. 29. A host cell transfected or transformed with the expression vector of claim 28. 30. An isolated nucleic acid consisting essentially of a unique fragment of a sequence selected from the group consisting of: SEQ.ID.NO. 1; SEQ.ID.NO. 12; SEQ.ID.NO. 13: SEQ.ID.NO. 14; the complement of SEQ.ID.NO. 1: the complement of SEQ.ID.NO. 12; the complement of SEQ.ID.NO. 13; and/or the complement of SEQ.ID.NO. 14. 31. The isolated nucleic acid of claim 30 wherein the fragment is between 200 and 2050 nucleotides in length. 32. The isolated nucleic acid of claim 30 wherein the fragment is 12. 13, 14. 15, 16. 17. 18. 19. 20. 21. 22, 23. 24. 25. 26. 27. 28. 29. 30, 31 and/or 32 nucleotides in length. 33. A kit for detecting the presence ofthe expression ofthe tumor rejection antigen precursor comprising a pair of isolated nucleic acid molecules constructed and arranged to selectively amplify the isolated nucleic acid molecule of claim 23. 34. The kit of claim 33 wherein the pair of isolated nucleic acid molecules are PCR primers. 35. An isolated tumor rejection antigen precursor coded for by the nucleic acid molecule of claims 23. 24, 25, 26 or 27. 36. A method for diagnosing a disorder characterized by expression of a RAGE tumor rejection antigen precursor which is processed to a RAGE derived tumor rejection antigen which forms a complex with HLA molecules, comprising: contacting a biological sample isolated from a subject with an agent that binds said complex, and determining binding between said complex and said agent as a determinant of said disorder. 37. A method for diagnosing a disorder characterized by expression of a RAGE tumor rejection antigen precursor coded for by a nucleic acid, comprising: contacting a biological sample isolated from a subject with an agent that is specific for said nucleic acid or an expression product thereof, wherein the nucleic acid hybridizes under stringent conditions to a molecule consisting ofthe nucleic acid sequence selected from the group consisting of: SEQ.ID.NO.1 ; SEQ.ID.NO.4; SEQ.ID.NO.6; SEQ.ID.NO.10; SEQ.ID.NO. 12; SEQ.ID.NO. 13: SEQ.ID.NO. 14: SEQ.ID.NO. 15; SEQ.ID.NO. 17; SEQ.ID.NO. 23; and SEQ.ID.NO. 35. and which codes for a tumor rejection antigen precursor, with the proviso that the isolated nucleic acid molecule does not code for a MAGE, GAGE or BAGE tumor rejection antigen precursor. and determining the interaction between said agent and said nucleic acid or said expression product as a determination of said disorder. 38. The method of claim 37 wherein the agent comprises a nucleic acid molecule selected from the group of molecules consisting of: SEQ.ID.NO. 1 ; SEQ.ID.NO. 12; SEQ.ID.NO. 13; SEQ.ID.NO. 14; a unique fragment of SEQ.ID.NO. 1 : a unique fragment of SEQ.ID.NO. 12; a unique fragment of SEQ.ID.NO. 13; and a unique fragment of SEQ.ID.NO. 14. 39. A method for treating a subject with a disorder characterized by expression of a RAGE tumor rejection antigen precursor, comprising administering to said subject an amount of an agent, which enriches selectively in the subject the presence of complexes of HLA and tumor rejection antigen that is derived from a tumor rejection antigen precursor coded for by a molecule as described in claims 23. 24. 25. 26 or 27. sufficient to ameliorate said disorder. 40. A method for treating a subject with a disorder characterized by expression of a RAGE tumor rejection antigen precursor, comprising administering to said subject an amount of autologous cytolytic T cells sufficient to ameliorate the disorder, the cytolytic T cells specific for complexes of an HLA molecule and a tumor rejection antigen that is derived from a tumor rejection antigen precursor coded for by a molecule as described in claims 23. 24. 25. 26 or 27 sufficient to ameliorate said disorder.

Inventors: BOON-FALLEUR THIERRY, BROUWENSTIJN NATHALIE, GAUGLER BEATRICE, SCHRIER PETER, VEN DEN EYNDE BENOIT, BOON-FALLEUR, THIERRY, BROUWENSTIJN, NATHALIE, GAUGLER, BEATRICE, SCHRIER, PETER, VEN DEN EYNDE, BENOIT
Applicants: LUDWIG INST CANCER RES, UNIV LEIDEN, LEIDEN UNIVERSITY, LUDWIG INSTITUTE FOR CANCER RESEARCH
Application year: 1996
Main classification: C12N15
IPC codes: A61K38, A61K39, A61K48, A61P35, A61P43, C07K14, C12N5, C12N15, C12P21, C12R1, G01N33